


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:48:50Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405374" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405374</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Obes Rep</journal-id><journal-id journal-id-type="iso-abbrev">Curr Obes Rep</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Current Obesity Reports</journal-title></journal-title-group><issn pub-type="epub">2162-4968</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405374</article-id><article-id pub-id-type="pmcid-ver">PMC12405374.1</article-id><article-id pub-id-type="pmcaid">12405374</article-id><article-id pub-id-type="pmcaiid">12405374</article-id><article-id pub-id-type="pmid">40892365</article-id><article-id pub-id-type="doi">10.1007/s13679-025-00660-w</article-id><article-id pub-id-type="publisher-id">660</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Villarroya</surname><given-names initials="F">Francesc</given-names></name><address><email>fvillarroya@ub.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Peyrou</surname><given-names initials="M">Marion</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Giralt</surname><given-names initials="M">Marta</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/021018s57</institution-id><institution-id institution-id-type="GRID">grid.5841.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0247</institution-id><institution>Departament de Bioqu&#237;mica i Biomedicina Molecular, </institution><institution>Departament de Bioqu&#237;mica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, </institution></institution-wrap>Avda Diagonal 643, Barcelona, Catalonia 08028 Spain </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01y43zx14</institution-id><institution>Institut de Biomedicina de la Universitat de Barcelona (IBUB), </institution></institution-wrap>Barcelona, Spain </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00gy2ar74</institution-id><institution-id institution-id-type="ISNI">0000 0004 9332 2809</institution-id><institution>Institut de Recerca de Sant Joan de D&#233;u, </institution></institution-wrap>08028 Barcelona, Spain </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02s65tk16</institution-id><institution-id institution-id-type="GRID">grid.484042.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 5930 4615</institution-id><institution> CIBER Fisiopatolog&#237;a de la Obesidad y Nutrici&#243;n (CIBEROBN), </institution></institution-wrap>Madrid, 28029 Spain </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>14</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">496088</issue-id><elocation-id>67</elocation-id><history><date date-type="received"><day>12</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>18</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="13679_2025_Article_660.pdf"/><abstract id="Abs1"><sec><title>Purpose of the Review</title><p id="Par1">This review summarizes recent evidence highlighting the specific role of adipose tissue in the systemic effects of incretin agonist-based drugs used in the treatment of obesity.</p></sec><sec><title>Recent Findings</title><p id="Par2">The development of incretin agonist-based drugs has achieved unprecedented success in the pharmacological treatment of obesity and the improvement of obesity-related comorbidities. While initially shown to significantly reduce adipose tissue through decreased food intake, incretin-based therapy is also increasingly reported to alter the properties of adipose tissue. Recent experimental and human studies indicate that these anti-obesity drugs induce significant changes in the metabolism and inflammatory state of adipose tissue, while also promoting its thermogenic plasticity.</p></sec><sec><title>Summary</title><p id="Par3">The direct and indirect actions of incretin-based anti-obesity drugs, which modify the properties of adipose tissue, are emerging as key contributors to the systemic health benefits of these treatments.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Glucagon-like peptide-1</kwd><kwd>Glucose-dependent insulinotropic peptide</kwd><kwd>Glucagon</kwd><kwd>White adipose tissue</kwd><kwd>Brown adipose tissue</kwd><kwd>Obesity</kwd></kwd-group><funding-group><award-group><funding-source><institution>Universitat de Barcelona</institution></funding-source></award-group><open-access><p>Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">Obesity has become a widespread global issue and 1 in 8 people worldwide were living with obesity in 2022 [<xref ref-type="bibr" rid="CR1">1</xref>]. The recommended lifestyle changes alone have very moderate weight-loss effects in people living with obesity, and bariatric surgery is currently considered the most effective treatment for inducing weight loss which, in addition to promoting weight loss, improves type 2 diabetes (T2D) and reduces various cardiometabolic risk factors [<xref ref-type="bibr" rid="CR2">2</xref>]. Bariatric surgery is regarded as relatively safe, but this invasive procedure can have significant side effects, and there is considerable variability in long-term outcomes among patients.</p><p id="Par5">Researchers have long sought to develop effective non-surgical pharmacological strategies to treat obesity. Historically, these efforts met limited success, having only modest effects on body weight and/or triggering harmful side effects. In recent years, the emergence of drugs that are based on incretins (a group of gut hormones increasing insulin secretion and stimulating a decay in blood glucose levels), such as those acting as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) agonists, has marked an unprecedented success in the treatment of obesity. Millions of people are now being treated with incretin agonism-based anti-obesity medications, making it a global priority to fully understand their action mechanisms and systemic effects and further enhance their safety and efficacy. Samms and Kusminski have recently provided an up-to-date, comprehensive overview of the current understanding of the mechanisms of action of incretin-based drugs and their significance in obesity research [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par6">GLP-1 is an incretin that is produced and secreted primarily by intestinal L cells, as well as by certain neurons and a subset of pancreatic &#945; cells in the islets of Langerhans [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. It acts on target tissues through interaction with the GLP-1 receptor (GLP-1R). GLP-1 helps to lower blood sugar by stimulating insulin secretion and inhibiting glucagon release. In the brain, GLP-1 reduces appetite; in the stomach, it slows gastric emptying; in insulin-sensitive tissues, such as muscle and adipose tissue, it enhances glucose uptake [<xref ref-type="bibr" rid="CR6">6</xref>]; in the liver, it inhibits glucose production [<xref ref-type="bibr" rid="CR7">7</xref>]. Additionally, GLP-1 has demonstrated cardioprotective effects [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par7">GIP is an incretin produced and secreted by intestinal K cells. Its receptor, GIPR, is found in pancreatic &#946;-cells as well as in many other tissues and organs. Like GLP-1, GIP is an incretin, so it lowers blood sugar by enhancing pancreatic insulin secretion [<xref ref-type="bibr" rid="CR8">8</xref>]. Additionally, GIP has been shown to act on other tissues, particularly affecting lipid metabolism and cardiovascular system [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par8">Both GLP1-R and GIPR are members of the G-protein coupled receptor family and, upon activation, induce adenylate cyclase activity and increase intracellular cAMP, which acts as a key intracellular mediator of their biological actions [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par9">Glucagon (GCG) is a peptide hormone produced and secreted by &#945; cells in the pancreas, mostly in response to fasting stimulus [<xref ref-type="bibr" rid="CR12">12</xref>]. GCG primarily functions to prevent glucose levels from falling too low by stimulating glucose production from the liver and regulating hepatic fatty acid metabolism. For its biological actions, glucagon acts on the glucagon receptor (GCGR), also a G-protein coupled receptor increasing cAMP when activated. GCGR is present preferentially in the liver but also in extra-hepatic cells and organs such as islet &#946; cells, brain, adipose tissue, heart, and kidney [<xref ref-type="bibr" rid="CR13">13</xref>]. Given the hyperglycaemic effect of GCG, it might seem counterintuitive to use GCG agonism in people living with obesity. However, it is well-known to induce satiety, slow emptying of the stomach and enhance energy expenditure [<xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref>]. Thus, in recent years it has been proposed that combining GCG agonism with incretin-based agonism could help optimize the pharmacological treatment of obesity.</p><p id="Par10">Body weight regulation is mainly governed by the brain and adipose tissue. The highly plastic adipose tissue serves multiple functions, ranging from the classical role of lipid storage in white adipose tissue (WAT) to the dissipation of energy through thermogenic processes, such as in brown adipose tissue (BAT). In obesity, the enlargement of WAT is associated with hypertrophy and, in some cases, hyperplasia of adipocytes, which enable WAT to increase fat storage in response to a positive energy balance [<xref ref-type="bibr" rid="CR17">17</xref>]. The brain and adipose tissue communicate via signalling networks, such as those mediated by adipose tissue-released adipokines, including leptin, adiponectin and many others. Adipokines act centrally and peripherally to regulate energy homeostasis and the metabolic response to changes in fat mass [<xref ref-type="bibr" rid="CR18">18</xref>]. Incretin agonism-based treatments, in association with their strong weight-reducing effects, significantly impact adipose tissue through both direct and indirect mechanisms, and they are likely to affect not only the quantity of adipose tissue but also its specific anatomical and cellular characteristics, and thus could have profound implications for patients&#8217; health.</p></sec><sec id="Sec2"><title>GLP-1R Agonism and White Adipose Tissue</title><sec id="Sec3"><title>GLP-1R Agonist Treatments and their Effects on Body Weight and Fat Mass</title><p id="Par11">Given the biological properties of GLP-1, researchers had long envisioned the potential of its therapeutic use. However, native GLP-1 proved to be of limited use as a drug candidate, because it exhibits rapid proteolytic degradation and renal clearance, and thus has a very short half-life. Peptidic GLP-1-based drugs were developed by introducing amino acid sequence changes and chemical additions that can prevent inactivation and favour stability without altering the agonist properties. Given the incretin effects of GLP-1, GLP-1R agonists were initially developed to treat T2D. However, it was clear from the initial clinical trials that GLP1-R agonist treatment reduced body weight [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par12">GLP-1R agonists first received approval by the US Food and Drug Administration in 2005 (exenatide) and for treatment of obesity in 2015 (liraglutide). More recently semaglutide was approved for treatment of obesity and overweight; compared to the previous GLP-1R agonists, it offers the significant benefits of once-weekly (instead of daily) treatment and a superior capacity to lower body weight (for a detailed review on the history of GLP-1R agonist drugs developments and effects on body weight see [<xref ref-type="bibr" rid="CR19">19</xref>]). Clinical results indicate that patients with obesity but not T2D receiving semaglutide show body weight reductions in the range of 15% [<xref ref-type="bibr" rid="CR20">20</xref>]. Recent data from the SELECT trial indicate that in patients living with obesity treated with semaglutide for up to 4 years, an average body weight reduction of 10% is observed [<xref ref-type="bibr" rid="CR21">21</xref>]. Although these decreases in body weight are smaller than those achieved by surgical procedures, they are highly significant for the clinical management of obesity.</p><p id="Par13">The weight reducing effects of GLP-1R agonists are primarily attributed to their ability to reduce food intake through central mechanisms [<xref ref-type="bibr" rid="CR22">22</xref>]. GLP-1R is expressed in neurons within the hindbrain and hypothalamus, where agonist-mediated GLP-1R activation translates into decreased food consumption [<xref ref-type="bibr" rid="CR23">23</xref>]. The consequent reduction in adipose tissue mass largely accounts for the body weight loss induced by GLP-1R agonists. Cohort studies found that the weight loss of liraglutide-treated patients living with obesity is primarily due to a decrease in fat mass, with minimal change seen in lean mass [<xref ref-type="bibr" rid="CR24">24</xref>]. In the case of semaglutide, a 68-week treatment in individuals living with overweight or obesity yielded an almost 20% reduction in total fat mass [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="Sec4"><title>Effects of GLP-1R Agonists on Adipose Tissue Distribution</title><p id="Par14">Despite the assumption that the reduction in adipose tissue accounts for most of the body weight reduction elicited by GLP-1R agonists, a few studies have measured the sizes of various adipose tissue depots in specific areas following GLP-1R agonist treatments. A recent meta-analysis found that treatment with liraglutide or exenatide reduces the mass of visceral adipose and, to a lesser degree, subcutaneous fat [<xref ref-type="bibr" rid="CR26">26</xref>]. A recent study reported that liraglutide treatment reduces visceral fat and causes a relative increase in subcutaneous fat deposition in the lower body, potentially reflecting depot-specific alterations in lipid metabolism [<xref ref-type="bibr" rid="CR27">27</xref>]. Similarly, preclinical studies in rats showed that liraglutide treatment preferentially reduced visceral fat compared to subcutaneous fat [<xref ref-type="bibr" rid="CR28">28</xref>]. These observations are relevant given that enlarged visceral adipose tissue is primarily responsible for obesity-related complications, while subcutaneous fat is generally considered to be neutral or even protective [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par15">A few studies have explored how liraglutide affects adipose tissue properties beyond changes in size. A recent study reported that liraglutide treatment increases the metabolic activity of visceral adipose tissue [<xref ref-type="bibr" rid="CR30">30</xref>] but another study performed using subcutaneous fat biopsies found that liraglutide did not improve in obesity-related dysfunction, particularly in terms of inflammation and fibrosis within subcutaneous adipose tissue [<xref ref-type="bibr" rid="CR31">31</xref>]. Meta-analyses, mainly derived from studies on patients with type 2 diabetes, found that liraglutide or exenatide treatment increased adiponectin levels [<xref ref-type="bibr" rid="CR32">32</xref>] and reduced leptin levels [<xref ref-type="bibr" rid="CR33">33</xref>], indicating that GLP-1R agonism has concordant effects on the size and secretome of adipose tissue.</p><p id="Par16">Data on the effects of semaglutide on adipose tissue are more limited. The DEXA-based analysis included in the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trial program [<xref ref-type="bibr" rid="CR34">34</xref>] indicated that semaglutide treatment notably reduces both total fat mass and regional visceral fat mass relative to baseline [<xref ref-type="bibr" rid="CR20">20</xref>], but this study did not explore potential differential effects on distinct adipose depots.</p><p id="Par17">In addition to the common assessment of the visceral and subcutaneous depots, several studies found reductions in the epicardial adipose tissue of patients receiving liraglutide [<xref ref-type="bibr" rid="CR35">35</xref>&#8211;<xref ref-type="bibr" rid="CR37">37</xref>] or semaglutide [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Epicardial adipose tissue is a type of fat that is closely attached to the myocardium; it plays a key role in cardiometabolic health, exerting harmful effects when it becomes enlarged [<xref ref-type="bibr" rid="CR40">40</xref>]. A recent study identified a particularly significant reduction in perirenal adipose tissue among individuals with obesity treated with liraglutide, which could conceivably improve obesity-related hypertension [<xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par18">In summary, the ability of GLP-1R agonists to reduce adipose tissue mass, particularly visceral fat, may have a clear impact on promoting metabolic health. A decrease in visceral adipose tissue size can potentially reduce inflammatory signalling and support a healthier adipokine secretion profile, as seen in patients who lose adipose tissue through non-pharmacological methods like lifestyle changes or bariatric surgery [<xref ref-type="bibr" rid="CR42">42</xref>].</p></sec><sec id="Sec5"><title>Mechanisms of Action of GLP-1R Agonism Treatment on WAT</title><p id="Par19">It remains unclear whether GLP-1R agonists have direct effects on adipose tissue, beyond their indirect effects mediated by central mechanisms and reduced food intake. It is generally believed that adipocytes express only minimal levels of GLP-1R; rather, its detection in bulk WAT samples is often attributed to its expression in non-adipocyte cells within the tissue. However, some studies have suggested that GLP-1R can show significant expression in human visceral adipose tissue, particularly in the stromal vascular fraction, which includes mesenchymal stem cells, preadipocytes, fibroblasts, vascular endothelial cells, and various immune cells [<xref ref-type="bibr" rid="CR43">43</xref>]. While one study reported that white adipocytes express GLP-1R at just over 10% of the level found in tissues that are highly responsive to GLP-1, such as the stomach [<xref ref-type="bibr" rid="CR43">43</xref>], other research found little to no GLP-1R expression in adipocytes and substantial expression only in non-adipocyte cells within the tissue, such as monocytes [<xref ref-type="bibr" rid="CR44">44</xref>]. It remains technically challenging to reliably measure GLP-1R levels in cells and tissues; as discussed by Drucker (2018) [<xref ref-type="bibr" rid="CR45">45</xref>], notably due to the lack of validity of the antibodies available. This may explain the remaining uncertainty regarding the presence of GLP-1R in adipose tissues. Further studies using knockout models in rodents may provide insight into the in vivo effects of deficiencies in these receptors.</p><p id="Par20">Several in vitro studies have shown effects of GLP-1R agonism on human white adipocytes and rodent models of adipogenesis. The results showed that GLP-1R agonists promote the differentiation of preadipocytes into white adipocytes and induce various metabolic effects, including increases in insulin-dependent glucose uptake, lipogenesis, lipolysis, and adiponectin secretion, and a reduction in pro-inflammatory signalling [<xref ref-type="bibr" rid="CR46">46</xref>&#8211;<xref ref-type="bibr" rid="CR48">48</xref>]. However, the physiological significance of these findings is uncertain, and it remains unclear whether any of the systemic effects elicited by GLP-1R agonists involve a direct action on adipocytes.</p><p id="Par21">Local inflammation at hypertrophied WAT is a hallmark of insulin resistance and other comorbidities associated with obesity. GLP-1R agonists reportedly reduce macrophage infiltration and inflammation at WAT in experimental models of obesity [<xref ref-type="bibr" rid="CR49">49</xref>]. Moreover, recent data indicate that GLP-1R agonist treatment restores the functionally defective natural killer (NKT) cells in people living with obesity, independently of its weight loss effect [<xref ref-type="bibr" rid="CR50">50</xref>]. Some evidence suggests that immune cells express GLP-1R, raising the possibility that this anti-inflammatory effect could result from a direct action of GLP-1 on non-adipocyte infiltrating immune cells within adipose tissue. However, a recent study indicated that the reduction in systemic inflammation caused by GLP-1R agonism occurs primarily via the central effects of GLP-1 [<xref ref-type="bibr" rid="CR51">51</xref>]. This recent study did not specifically address obesity-related adipose tissue inflammation, and the potential for GLP-1R agonism to directly influence immune cells within adipose tissue and thereby mitigate local inflammation remains an open question (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Mechanisms of action of GLP-1 on WAT. GLP-1 targets the central nervous system via the GLP-1 receptor, promoting satiety and resulting in a negative energy balance that reduces adipocyte size and lipid content. Although this is not a consensually accepted view (as indicated by the dotted arrows and question marks), there is evidence proposing that GLP-1 can directly act on macrophages within WAT to reduce inflammation, on pre-adipocytes to promote adipogenic differentiation, and on white adipocytes to regulate metabolism</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="13679_2025_660_Fig1_HTML.jpg"/></fig></p></sec></sec><sec id="Sec6"><title>GIPR Agonism and WAT</title><sec id="Sec7"><title>Incorporating GIPR Agonism with GLP-1R Agonism: Effects on Body Weight and Adiposity</title><p id="Par22">Recent years have seen remarkable advancements in obesity treatment achieved by the development of new drugs that combine GLP-1R and GIPR co-agonism in a single molecule. The efforts to develop these dual agonists were initially aimed at improving glucose metabolism in T2D through additive insulinotropic effects and promote greater weight loss by further reducing food intake. However, there is an ongoing debate on whether increasing or decreasing GIPR agonism can benefit body weight and metabolism, in part based on the observation that GIPR-null mice are protected against obesity [<xref ref-type="bibr" rid="CR52">52</xref>]. The use of GLP-1R agonism plus GIPR antagonism has paradoxically shown positive results similar to those obtained with GLP1-GIPR agonists in preclinical studies. Similar evidence in humans remain in phase I settings [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. To date, the only FDA-approved drug involving GIPR action, tirzepatide, combines GLP-1R and GIPR agonism. It was approved in 2022 for the treatment of T2D and later in 2023 for the treatment of obesity.</p><p id="Par23">Multiple clinical trials showed that tirzepatide enhances weight loss efficacy and yields impressive reductions in body weight relative to results obtained using a single GLP-1R agonist [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. In fact, preclinical studies had already shown that molecules combining GLP-1R and GIPR agonism are more effective than GLP-1R agonists alone in promoting weight loss and reducing food intake [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. A key distinction between agonism of GLP-1R/GIPR agonism and that of GLP-1R alone may lie in the peripheral effects of GIPR agonism, which arise from the broader expression (including in adipose tissue) of GIPR compared to GLP-1R. Mice lacking GIPR in the central nervous system showed complete abolition of the GIP-driven inhibition of food intake but only partial reduction of GIP-induced weight loss [<xref ref-type="bibr" rid="CR59">59</xref>]. This suggested that GIPR agonism promotes weight loss through both central inhibition of food intake and peripheral mechanisms unrelated to food intake. However, other studies did not find significant effects of GIP on body weight in mice with deletion of GIPR in inhibitory GABAergic neurons [<xref ref-type="bibr" rid="CR60">60</xref>]. For tirzepatide treatment, only around 20% of the improvement achieved in insulin sensitivity can be attributed to weight loss [<xref ref-type="bibr" rid="CR61">61</xref>], whereas for single GLP-1R agonists the enhancement in insulin sensitivity is entirely attributable to weight loss [<xref ref-type="bibr" rid="CR62">62</xref>]. Moreover, experimental tirzepatide treatment exerts systemic anti-inflammatory effects even in mice lacking GLP1R in the brain [<xref ref-type="bibr" rid="CR51">51</xref>]. These findings have heightened interest in clarifying the role of GIP action on peripheral tissues, particularly adipose tissue, and whether such effects mediate some of the pharmacological effects of GIPR agonism.</p></sec><sec id="Sec8"><title>Effects of GIPR Agonism in WAT</title><p id="Par24">Several clinical trials showed that tirzepatide treatment significantly reduces the masses of total fat and visceral adipose tissue. Compared to treatments based on single GLP-1 receptor agonism (e.g., semaglutide) over the same duration, tirzepatide demonstrated superior decreases in both total and visceral adipose tissue [<xref ref-type="bibr" rid="CR63">63</xref>]. In patients living with T2D, tirzepatide treatment was reported to preferentially reduce visceral over subcutaneous adipose tissue, suggesting that the treatment triggered a shift toward a healthier fat distribution pattern [<xref ref-type="bibr" rid="CR64">64</xref>]. However, another study reported similar decreases in visceral and subcutaneous abdominal fat following tirzepatide treatment [<xref ref-type="bibr" rid="CR65">65</xref>].</p></sec><sec id="Sec9"><title>Cellular Basis of GIP Action on WAT</title><p id="Par25">In rodents and humans, WAT expresses the transcript encoding GIPR [<xref ref-type="bibr" rid="CR66">66</xref>]; the level is higher in visceral adipose tissue compared to subcutaneous adipose tissue, and the GIPR transcript is downregulated under insulin resistance [<xref ref-type="bibr" rid="CR67">67</xref>]. There is a debate regarding which cells within WAT are responsible for this expression. Some studies suggest that GIPR is predominantly expressed in non-adipocyte cell types within WAT [<xref ref-type="bibr" rid="CR68">68</xref>], while others indicate that white adipocytes from both mice and humans express significant levels of GIPR, even though still lower than in the stromal vascular fraction [<xref ref-type="bibr" rid="CR69">69</xref>], but this expression is induced during adipocyte differentiation [<xref ref-type="bibr" rid="CR70">70</xref>]. A recent study has convincingly demonstrated that a fluorescently labeled selective GIPR mono-agonist (GIPRA-FL) associates with adipocyte membranes, and GIPR expression in adipocytes was shown to mediate intracellular signaling in response to GIP, thereby regulating functional cellular responses [<xref ref-type="bibr" rid="CR69">69</xref>]. These findings support a direct role for GIP in modulating adipocyte function. The study further reveals that the dual GIPR/GLP-1R agonist tirzepatide directly associates with adipocytes and activates intracellular signaling specifically through GIPR engagement. This functional GIPR expression, responsive to both tirzepatide and GIP, has been demonstrated in both human and mouse adipocytes. Collectively, these findings indicate the presence of active GIPR-dependent signaling in white adipocytes and suggest that tirzepatide may modulate adipocyte function through GIPR agonism. Moreover, multiple studies show that GIP treatment of adipocytes in vitro exerts direct metabolic effects, including increased insulin sensitivity and glucose uptake [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. Recent data based on single nuclei RNAseq analysis of WAT confirmed substantial expression of GIPR transcript in adipocytes [<xref ref-type="bibr" rid="CR73">73</xref>].</p><p id="Par26">GIPR agonism affects glucose metabolism in WAT. In the absence of GLP-1R, treatment with tirzepatide or the long-acting GIPR agonist, LAGIPRA, improves insulin sensitivity by enhancing glucose disposal in WAT; moreover, at least some degree of the tirzepatide-induced improvement of insulin sensitivity occurs to some extent in a weight-independent manner [<xref ref-type="bibr" rid="CR74">74</xref>]. This aligns with the evidence showing that GIP can increase glucose uptake in adipose tissue [<xref ref-type="bibr" rid="CR69">69</xref>].</p><p id="Par27">GIP significantly affects lipid metabolism in adipocytes, promoting lipolysis [<xref ref-type="bibr" rid="CR75">75</xref>] and enhancing lipoprotein lipase activity [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. It also promotes fatty acid re-esterification [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. Tirzepatide shows similar effects, increasing the hydrolysis of dietary triglycerides and fatty acid uptake in adipose tissue [<xref ref-type="bibr" rid="CR69">69</xref>]. Although the role of GIP in fat metabolism may seem contradictory to its ability to reduce fat mass, recent views suggest GIPR agonism supports healthy WAT expansion by clearing triglycerides and preventing lipotoxicity, alongside its ability to reduce fat mass through lower food intake, and thereby reduces insulin resistance and other obesity-related comorbidities [<xref ref-type="bibr" rid="CR80">80</xref>].</p><p id="Par28">A recent study proposed that GIPR agonism can have differential effects on adipose tissue and metabolism depending on the feeding status, and this is linked to the action of insulin [<xref ref-type="bibr" rid="CR69">69</xref>]. In the fed state, which is characterized by high insulin levels, GIPR agonism promotes triglyceride clearance by increasing lipoprotein lipase activity, along with fatty acid and glucose uptake. This contrasts with the fasting state, wherein insulin levels are low and GIP action inducing lipolysis predominates (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). It should be noted that tirzepatide-induced GIP differs from natural GIP stimuli, in that the former has a prolonged action that extends beyond the postprandial period into the post-absorptive phase, whereas the effects of natural GIP occur only in the post-meal period. This sustained pharmacological GIPR agonism has been proposed to govern the non-obesogenic and even leaning effects embodied by the GIPR agonism in the dual GLP-1R-GIPR agonists. GIP acts on its cellular targets by binding to GIPR, triggering intracellular G&#945;s-mediated cAMP production and &#946;-arrestin recruitment [<xref ref-type="bibr" rid="CR81">81</xref>]. Recent studies identified human GIPR variants with differing abilities to activate these two signalling pathways and showed that the balance between them appears to influence GIPR agonism effects. For example, a variant associated with lower cAMP and &#946;-arrestin signalling is strongly linked to reduced adiposity. It has been suggested the GIPR agonism of tirzepatide may mimic the actions of native GIP but with reduced recruitment of &#946;-arrestin recruitment to GLP-1R but full activation of the cAMP pathway, thereby contributing to the ability of tirzepatide to decrease adiposity [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>].<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Mechanisms of action of GIP on WAT. GIP can target pre-adipocytes and adipocytes via GIPR. In adipocytes, GIP promotes insulin-dependent glucose uptake and alters lipid metabolism distinctly according to the fed (high insulin levels) or fasted (low insulin levels) state. It also promotes lipid oxidation in the white adipocyte to increase whole body energy expenditure via activation of the SERCA-driven futile calcium cycle. FA, fatty acid, LPL, lipoprotein lipase</p></caption><graphic id="MO2" position="float" orientation="portrait" xlink:href="13679_2025_660_Fig2_HTML.jpg"/></fig></p><p id="Par29">Finally, a recent study highlights the direct effects of GIPR agonism in promoting energy expenditure in WAT [<xref ref-type="bibr" rid="CR73">73</xref>]. Several preclinical and clinical data suggest a role for GIPR agonism, as seen in dual GLP-1/GIPR agonists, in enhancing energy expenditure as part of their anti-obesity effects. This has led to investigations into their potential role in BAT activation and the browning of WAT (see Sect. <xref rid="Sec5" ref-type="sec">5</xref>). Yu and collaborators reported that GIPR agonism protects against obesity in mice by inducing thermogenesis in WAT itself through the promotion of the Sarcoendoplasmic Reticulum Calcium ATPase (SERCA)-driven futile calcium cycle [<xref ref-type="bibr" rid="CR73">73</xref>]. Specifically, the authors used an inducible adipose tissue-specific mouse model of GIPR overexpression, which enabled them to identify a mechanism whereby GIPR induction exclusively in the white adipocyte promotes activation of SERCA-mediated futile calcium cycling, to increase adipose tissue lipid oxidation and whole body energy expenditure. This metabolic pathway is based on an ATP-hydrolyzing mechanism elicited by futile calcium cycling, originally known to favor energy expenditure in muscle and beige adipocytes [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. Very recently, Kajimura and colleagues demonstrated that microsomal thermogenesis in adipocytes modulates SERCA2b-mediated Ca&#178;&#8314; import [<xref ref-type="bibr" rid="CR85">85</xref>], a process that plays a central role in UCP1-independent thermogenesis and energy homeostasis. This finding further underscores the relevance of futile calcium cycling in adipocytes, particularly in the context of its modulation by GIPR agonism, as discussed above.</p></sec></sec><sec id="Sec10"><title>Glucagon Receptor Agonism and Obesity Treatment</title><sec id="Sec11"><title>Incorporating Glucagon Receptor Agonism To Drugs for Obesity Treatment: Implications for Adiposity</title><p id="Par30">Glucagon receptor (GCGR) recently emerged as an additional target in the development of anti-obesity drugs. Beyond its role in pancreatic function, GCG has gained recognition as a regulator of energy balance, and several studies have explored its potential as a weight-regulatory hormone. In preclinical animal models, GCGR agonism has been shown to reduce food intake and especially to increase energy expenditure, contributing to weight loss [<xref ref-type="bibr" rid="CR86">86</xref>]. GLP-1R/GCGR unimolecular co-agonists have been developed to leverage the complementary pharmacological benefits of GCG&#8217;s powerful promotion of energy expenditure and GLP-1&#8217;s anorectic (appetite-reducing) and glucose-lowering effects, while using the presence of GLP-1R agonism to minimize potential adverse effects of GCGR agonism (such as glycaemic effects leading to diabetogenic risks). On preclinical studies, several GLP-1R/GCGR co-agonists have demonstrated superior weight loss, glucose regulation, and food intake reduction effects compared to those of single GLP-1R agonists [<xref ref-type="bibr" rid="CR87">87</xref>&#8211;<xref ref-type="bibr" rid="CR89">89</xref>]. Some of these co-agonists have moved into clinical development, where they yield notable improvements in body weight and often improved comorbidities such as hypertension [<xref ref-type="bibr" rid="CR90">90</xref>] or metabolic dysfunction-associated steatohepatitis [<xref ref-type="bibr" rid="CR91">91</xref>]. Although no GLP-1R/GCGR co-agonist is yet approved for clinical use, a number are currently under phase 2 or phase 3 trials for treatment of obesity and comorbidities (for updated review see [<xref ref-type="bibr" rid="CR56">56</xref>]).</p><p id="Par31">Researchers next sought to combine agonists for GCGR, GLP-1R, and GIPR into a single molecule (a tri-agonist) that activates all three receptors [<xref ref-type="bibr" rid="CR92">92</xref>], each providing unique metabolic benefits: GLP-1R reduces food intake and improves glycaemic control, GCGR boosts energy expenditure, and GIPR may enhance GLP-1&#8217;s satiety effects and improve insulin sensitivity. Several tri-agonist peptides have been developed to date [<xref ref-type="bibr" rid="CR93">93</xref>]; they show superior results in regulating body weight, liver lipid metabolism, and glycaemic control compared to existing treatments. Early clinical trials of some tri-agonists (e.g. retatrutide) have yielded significant body weight reductions (24&#8211;28%) in individuals living with obesity after 48 weeks of treatment [<xref ref-type="bibr" rid="CR94">94</xref>]. Clinical trials of dual or triple agonists involving GCGR agonism, have not specifically provided data on the impact of these drugs on adipose distribution and properties but fat loss is generally believed to drive the body weight reductions triggered by these drugs.</p></sec><sec id="Sec12"><title>Glucagon and WAT</title><p id="Par32">The role of GCG in WAT has not been extensively studied; to date, the research has focused more on its energy expenditure-increasing effects potentially mediated by BAT (see below). WAT expresses GCGR, but at lower levels than seen in the liver [<xref ref-type="bibr" rid="CR95">95</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. GCG was thought to induce lipolysis in WAT via G-protein coupled receptor action, but recent studies in mice with adipose-specific GCGR invalidation failed to show any significant metabolic effect [<xref ref-type="bibr" rid="CR97">97</xref>]. GCG has been reported to induce lipolysis in vitro in isolated adipocytes but there is some question as to the physiological relevance of these studies, which often used high doses of GCG [<xref ref-type="bibr" rid="CR98">98</xref>&#8211;<xref ref-type="bibr" rid="CR101">101</xref>]. Moreover, a microdialysis study of subcutaneous adipose tissue in humans found that GCG had no significant effect on lipolysis [<xref ref-type="bibr" rid="CR102">102</xref>]. In summary, it remains unclear whether GCG action has direct effects on WAT, with recent data supporting mainly indirect effects. In this sense, experimental evidence indicates that GCG targets the liver where it promotes the secretion of fibroblast growth factor-21(FGF21) [<xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR104">104</xref>], a hormonal factor involved in regulating energy balance by targeting both the central nervous system and peripheral tissues, including WAT and BAT (see below). Therefore, it cannot be ruled out that GCG exerts indirect effects on WAT by promoting the secretion of FGF21, and possibly other regulatory hepatokines, that can target WAT.</p></sec></sec><sec id="Sec13"><title>A Role for Thermogenic Plasticity of Adipose Tissue in the Actions of incretin-based anti-obesity Drugs</title><sec id="Sec14"><title>Thermogenic Plasticity of Adipose Tissue in Obesity and Metabolic Health</title><p id="Par33">BAT is a type of adipose tissue specialized in heat production and is associated with energy expenditure, in contrast to the metabolic energy-storing function of WAT. The thermogenic activity of BAT is driven by uncoupled mitochondrial oxidation in brown adipocytes via the UCP1 protein, stimulated by the sympathetic nervous system and endocrine factors in response to temperature or diet [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]. Rodent studies show that active BAT helps prevent obesity by increasing energy expenditure and aiding in the removal of glucose and lipids from the bloodstream [<xref ref-type="bibr" rid="CR107">107</xref>&#8211;<xref ref-type="bibr" rid="CR109">109</xref>]. BAT also secretes brown adipokines that affect various tissues systemically [<xref ref-type="bibr" rid="CR110">110</xref>]. Active BAT&#8217;s role in adult humans was discovered around 15 years ago, and though its role in obesity protection is debated, studies have linked it to reduced obesity, type 2 diabetes, and cardiovascular disease [<xref ref-type="bibr" rid="CR111">111</xref>]. WAT can also develop a thermogenic phenotype through &#8220;browning,&#8221; [<xref ref-type="bibr" rid="CR112">112</xref>], a process by which &#8220;beige&#8221; adipocytes, showing a brown adipocyte-like multilocular morphology and thermogenic capacity mediated by UCP1 and futile cycles, appear in WAT depots [<xref ref-type="bibr" rid="CR113">113</xref>&#8211;<xref ref-type="bibr" rid="CR115">115</xref>]. Given that the thermogenic plasticity of adipose tissue is important for energy expenditure and metabolic homeostasis, BAT activation and WAT browning have been widely targeted in the development of anti-obesity drugs. However, the reliance on sympathomimetics for this purpose has resulted in their systematic rejection to date due to harmful cardiovascular side effects [<xref ref-type="bibr" rid="CR116">116</xref>]. With the emergence of incretin agonism-based drugs researchers have begun exploring how much of their effects are embodied through promoting activities of thermogenic adipose tissues.</p></sec><sec id="Sec15"><title>Effects of GLP-1R Agonism on the Thermogenic Plasticity of Adipose Tissue</title><sec id="Sec16"><title>GLP-1R Agonists Promote BAT Activity and WAT Browning in Preclinical Models</title><p id="Par34">Several preclinical studies in mouse models have suggested that the weight loss induced by GLP-1R agonists is not due solely to their anorectic effects but also may involve changes in energy expenditure that occur through the activation of BAT and/or the recruitment of beige adipocytes in WAT [<xref ref-type="bibr" rid="CR117">117</xref>]. This happens largely via indirect mechanisms that are mediated by central GLP-1R activation and at least partially depend on sympathetic nervous system signalling to thermogenic adipose tissues [<xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR119">119</xref>]. Thus, administration of GLP-1R agonists into the hypothalamic ventromedial nucleus increases sympathetic nervous system activity leading to enhancement of BAT thermogenesis and browning of WAT [<xref ref-type="bibr" rid="CR120">120</xref>]. Intracerebroventricular injection of exendin-4 similarly increased sympathetic outflow to both BAT and WAT, resulting in higher thermogenesis in mice [<xref ref-type="bibr" rid="CR121">121</xref>]. Intraperitoneal administration of liraglutide also reportedly increased oxygen consumption, UCP1 levels and type 2 deiodinase activity in BAT and subcutaneous WAT [<xref ref-type="bibr" rid="CR122">122</xref>]. These results collectively underscore BAT activation and WAT browning driven by central effects of GLP-1R agonism and subsequent sympathetic activation; however, further studies are needed to establish the role of these effects in the systemic metabolic and body weight changes in response to GLP-1R agonism-based drugs.</p></sec><sec id="Sec17"><title>Human Studies Addressing the Effects of GLP-1R Agonism on BAT</title><p id="Par35">Unlike the findings from preclinical studies, the evidence available from humans suggests that GLP-1R agonist-induced weight loss is primarily mediated by reduced appetite and energy intake rather than increased energy expenditure [<xref ref-type="bibr" rid="CR123">123</xref>]. A systematic review and meta-analysis [<xref ref-type="bibr" rid="CR124">124</xref>] concluded that the GLP-1R agonists, exenatide and liraglutide, have neutral effects on resting energy expenditure.</p><p id="Par36">To date, only two studies have investigated the potential effects of GLP-1R agonists on human BAT [<xref ref-type="bibr" rid="CR125">125</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]. The first such study found that 26-week liraglutide treatment of patients living with T2D did not reduce the fat fraction in BAT (a surrogate of BAT activity) or alter resting energy expenditure [<xref ref-type="bibr" rid="CR125">125</xref>]. The second study found that 12 weeks exenatide treatment reduced body weight without affecting resting energy expenditure but increased the metabolic volume and glucose uptake in both cervical and supraclavicular BAT [<xref ref-type="bibr" rid="CR126">126</xref>], as measured by [18&#160;F] fluorodeoxyglucose positron emission tomography, which is the gold-standard method for measuring BAT activity in humans [<xref ref-type="bibr" rid="CR127">127</xref>]. This significant finding in young, non-diabetic, lean adults, supports the idea that GLP-1R agonism contributes to activating BAT. Moreover, a recent case report highlighted increased BAT activity in a woman with obesity treated with the GLP-1R agonist semaglutide [<xref ref-type="bibr" rid="CR128">128</xref>]. Further studies specifically evaluating BAT activity in individuals living with obesity treated with GLP-1R agonist-based therapies are needed to draw firm conclusions on BAT activation in patients.</p></sec><sec id="Sec18"><title>Immune cell-based Mechanisms Contributing To the Effects of GLP-1R Agonism on Thermogenic Adipose Tissue</title><p id="Par37">As discussed earlier, it remains unclear whether GLP-1R agonists act directly on adipose tissues, including thermogenic fat. However, recent preclinical studies have shed new light on the involvement of immune cells in the thermogenic activation of adipose tissues observed under GLP-1R agonism [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR129">129</xref>]. The results from these studies suggest that GLP-1 signalling may target immune cells, such as monocytes/macrophages within adipose tissues, which could directly affect adipose tissue functions. In mice, peripheral administration of liraglutide activates invariant NKT (iNKT) cells in WAT, increasing FGF21 production to promote the browning of inguinal WAT and contribute to weight loss [<xref ref-type="bibr" rid="CR129">129</xref>]. Indeed, it has been shown that FGF21 is required for weight loss induced by liraglutide in male mice [<xref ref-type="bibr" rid="CR130">130</xref>]. In iNKT-deficient mice, liraglutide promotes satiety but fails to induce FGF21, leading to reduced weight loss. Remarkably, humans treated with liraglutide also exhibit increased peripheral levels of iNKT cells and FGF21, both of which correlate with the degree of weight loss induced by the therapy [<xref ref-type="bibr" rid="CR129">129</xref>]. A recent study revealed that intraperitoneal liraglutide administration in mice leads to a transient upregulation of monocyte interleukin-6 (IL-6) secretion, raising circulating IL-6 levels and directly targeting IL-6 receptor signalling in preadipocytes/adipocytes. The ability of liraglutide to induce energy expenditure, brown adipogenesis and thermogenesis requires the presence of active IL-6 receptor [<xref ref-type="bibr" rid="CR44">44</xref>]. Interestingly, exenatide treatment in humans living with prediabetes also acutely induced IL-6 secretion by monocytes and increased systemic IL-6 levels [<xref ref-type="bibr" rid="CR44">44</xref>]. Although IL-6 can be considered a pro-inflammatory cytokine, it may have positive functions for metabolic health depending on its site of synthesis and secretion [<xref ref-type="bibr" rid="CR131">131</xref>]. In fact, IL-6 acts as a &#8220;batokine,&#8221; when its secretion by brown adipocytes is induced in response to sympathetic stimulation [<xref ref-type="bibr" rid="CR132">132</xref>].</p><p id="Par38">The results of these studies emphasize that crosstalk between immune cells and adipocyte lineages capable of adopting beige and/or brown thermogenic phenotypes is important for the ability of GLP-1R agonism to promote the thermogenic plasticity of adipose tissue (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Mechanisms of action of GLP-1 on BAT and WAT browning. GLP-1 targets the central nervous system through the GLP-1 receptor, which activates the sympathetic nervous system and induces noradrenergic signalling to BAT and browning-prone WAT. Additionally, GLP-1 interacts with GLP-1R on invariant natural killer T (iNKT) cells and macrophages, stimulating the secretion of FGF21 and IL-6, both of which promote WAT browning. NE, norepinephrine</p></caption><graphic id="MO3" position="float" orientation="portrait" xlink:href="13679_2025_660_Fig3_HTML.jpg"/></fig></p></sec></sec><sec id="Sec19"><title>Effects of GIPR Agonism on Brown Adipose Tissue and Adipose Tissue Browning</title><sec id="Sec20"><title>Multi-receptor Drugs Containing GIPR Agonism Activate BAT and Promote Adipose Tissue Browning in Preclinical Studies</title><p id="Par39">Following the incorporation of GIPR agonism activity into dual receptor agonist drugs (e.g. tirzepatide), several studies have investigated whether such activity impacts BAT thermogenic activity and WAT browning to promote energy expenditure and thereby contribute to weight loss. Preclinical studies in mice showed that the positive effects of dual GLP-1R/GIPR agonism on body weight reduction in mice include a significant increase in energy expenditure [<xref ref-type="bibr" rid="CR58">58</xref>]. Among humans, patients treated with semaglutide or tirzepatide and having comparable energy intake, the latter lose more weight, potentially through enhancement of energy expenditure [<xref ref-type="bibr" rid="CR133">133</xref>]. Although the literature currently lacks direct robust data on how tirzepatide impacts energy expenditure in patients, preliminary data from the <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT04081337">NCT04081337</ext-link> trial have been used to suggest that tirzepatide may attenuate the adaptive reduction in energy expenditure occurring in association with weight loss [<xref ref-type="bibr" rid="CR134">134</xref>].</p><p id="Par40">Experimental studies in diet-induced obese mice have shown that tirzepatide treatment enhances glucose uptake, upregulates genes associated with thermogenic activation and metabolic catabolism [<xref ref-type="bibr" rid="CR74">74</xref>] and induces a thermogenic-like amino acid signature [<xref ref-type="bibr" rid="CR135">135</xref>] in BAT. Tirzepatide administration in mice can decrease the circulating levels of branched-chain amino acids (BCAA) and ketoacids [<xref ref-type="bibr" rid="CR74">74</xref>], and defective BCAA catabolism in thermogenic adipose tissues can impair thermogenesis [<xref ref-type="bibr" rid="CR136">136</xref>]. Notably, the effects of tirzepatide in individuals living with T2D include significant reductions in BCAA and related metabolites [<xref ref-type="bibr" rid="CR137">137</xref>]. The effects of tirzepatide on BAT and the browning of WAT have been attributed to the GIPR agonism component, as these effects of tirzepatide are largely mimicked by treatment with the long-acting GIPR agonist LAGIPRA [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]. However, this assumption, based on mouse models, should be approached with caution, given the evidence that, unlike in humans, tirzepatide is less potent at the mouse GIPR than mouse GIP [<xref ref-type="bibr" rid="CR139">139</xref>]. To date, the effects of GIPR agonism on BAT have not yet been thoroughly assessed in humans. However, while acute GIP infusion does not appear to alter energy expenditure in humans [<xref ref-type="bibr" rid="CR140">140</xref>], 6 days of subcutaneous GIP infusion can increase the temperature of the supraclavicular area, which is a primary site of BAT depots [<xref ref-type="bibr" rid="CR141">141</xref>].</p></sec><sec id="Sec21"><title>Mechanisms Through Which GIPR Agonism Promotes Adipose Thermogenic Plasticity</title><p id="Par41">Although studies using tirzepatide and other molecules with GIPR agonism generally show thermogenic activation of BAT and WAT, research involving genetic invalidation of GIPR has yielded somewhat contradictory results. This appears analogous to the paradoxically similar abilities of GIPR agonist treatment and genetic invalidation of GIPR to protect mice against diet-induced obesity.</p><p id="Par42">The GIPR transcript is expressed in BAT at levels similar to those seen in other adipose depots [<xref ref-type="bibr" rid="CR66">66</xref>]. This expression arises preferentially in the brown adipocyte fraction of the tissue [<xref ref-type="bibr" rid="CR66">66</xref>], but GIPR is also expressed in other cell types (e.g., immune cells) within BAT and in browning-prone WAT depots. The literature currently lacks solid data on GIPR protein levels in distinct cell types within thermogenic adipose tissue.</p><p id="Par43">Selective loss of GIPR within BAT (but not in potentially thermogenic inguinal WAT) does not significantly alter energy expenditure or metabolism in mice under feeding of an obesogenic diet [<xref ref-type="bibr" rid="CR66">66</xref>]. In contrast, invalidation of GIPR in myeloid cells decreases energy expenditure, inhibits the WAT browning [<xref ref-type="bibr" rid="CR142">142</xref>], increases inflammation, and reduces the synthesis of type 2 cytokines within adipose tissue [<xref ref-type="bibr" rid="CR143">143</xref>]. This aligns with the known role of inflammation in repressing adipose thermogenic activity and the importance of type 2 immunity in activating BAT and beige adipose tissue [<xref ref-type="bibr" rid="CR144">144</xref>]. In vitro studies have shown that GIP treatment increases the expression of the thermogenic marker gene <italic toggle="yes">UCP1</italic> and the secretion of IL-6. However, paradoxically, GIPR gene knockout also leads to increased expression of <italic toggle="yes">UCP1</italic> and other genes related to BAT thermogenesis and metabolism [<xref ref-type="bibr" rid="CR66">66</xref>]. Another study found that GIP treatment increases the browning of in vitro cultured adipose precursor cells from omental WAT[<xref ref-type="bibr" rid="CR145">145</xref>].</p><p id="Par44">In summary, it appears that GIPR agonism has a widespread capacity to induce the thermogenic plasticity of adipose tissue by targeting distinct cell types within the tissue, such as brown adipocytes, beige adipocytes and especially immune cells, which are key mediators of thermogenic remodelling of adipose tissue (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). As mentioned above, a recent report demonstrated that GIPR can induce lipid oxidation and thermogenesis in white adipocytes to increase energy expenditure by promoting SERCA-calcium futile cycling, even in the absence of a clear acquisition of beige morphology [<xref ref-type="bibr" rid="CR73">73</xref>].<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Mechanisms of action of GIP on BAT and WAT browning. GIP targets GIPR in macrophages, resulting in reduced inflammation and increased synthesis of type 2 cytokines, which promote WAT browning. Additionally, GIP induces the thermogenic activation of adipose tissue by interacting with GIPR in brown and beige adipocytes, while also promoting the browning of WAT by acting on pre-adipocytes. Additionally, white adipocytes contribute to energy expenditure via lipid oxidation and activation of the SERCA-driven futile calcium cycle (see 3.3)</p></caption><graphic id="MO4" position="float" orientation="portrait" xlink:href="13679_2025_660_Fig4_HTML.jpg"/></fig></p></sec></sec><sec id="Sec22"><title>The Potential of GCGR Agonism in Promoting Adipose Tissue Thermogenic Plasticity</title><sec id="Sec23"><title>Glucagon Agonism as a Potential Tool To Promote Energy Expenditure in incretin-based Treatments against Obesity</title><p id="Par45">The rationale for incorporating GCGR agonism into multi-receptor incretin-based drugs stems from findings indicating that GCG can increase energy expenditure. For example, GCG has been shown to induce energy expenditure in various preclinical animal models (see [<xref ref-type="bibr" rid="CR86">86</xref>] and [<xref ref-type="bibr" rid="CR146">146</xref>] for review), offering protection against diet-induced obesity. In humans, GCG infusion has been reported to increase energy expenditure in both lean people and individuals living with obesity [<xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR148">148</xref>], although not all studies have confirmed this effect [<xref ref-type="bibr" rid="CR149">149</xref>]. Limited data have directly confirmed that GCGR agonism in dual (GLP-1R/GCGR) or triple (GLP-1/GIP/GCGR) agonist drugs provide the same benefits promoting energy expenditure. In reports on experimental studies, the weight loss achieved by the GLP-1R/GCG co-agonist MEDI0382 has been partially attributed to GCGR-dependent induction of energy expenditure [<xref ref-type="bibr" rid="CR150">150</xref>]. In humans, GCG has shown a strong capacity to induce energy expenditure when combined with a single GLP-1R agonist in individuals living with obesity [<xref ref-type="bibr" rid="CR151">151</xref>]. Recent data on individuals living with overweight and obesity treated with the GLP-1R/GCGR co-agonist SAR425899 indicated that such individuals exhibit a smaller-than-expected decrease in the sleeping metabolic rate, increased fat oxidation but no overt induction of energy expenditure [<xref ref-type="bibr" rid="CR152">152</xref>].</p></sec><sec id="Sec24"><title>Effects of Glucagon Agonism on BAT and WAT Browning and the Relationship with Energy Expenditure</title><p id="Par46">Accumulated evidence indicates that GCG treatment activates BAT thermogenesis in preclinical models, in association with increased energy expenditure (for review see [<xref ref-type="bibr" rid="CR86">86</xref>]). The relevant effects of GCG include upregulation of UCP1 expression and sustained effects on BAT recruitment, including mitochondrial biogenesis and hypertrophy of thermogenically active BAT. Recently, GCG was reported to induce WAT browning in a GCGR-dependent fashion [<xref ref-type="bibr" rid="CR153">153</xref>]. Furthermore, a study reported that treating mice with the dual GLP-1/GCG agonist cotadutide activates BAT thermogenesis; however, the relative contributions of GLP-1 and GCG agonism was not assessed [<xref ref-type="bibr" rid="CR154">154</xref>]. Recently, a superior efficacy of dual GLP-1R/GCGR agonism versus single GLP-1 agonism in reducing obesity in mice has been attributed to a remodelling of WAT towards browning and UCP-1-dependent BAT activation [<xref ref-type="bibr" rid="CR155">155</xref>].</p><p id="Par47">However, the role of BAT activation in GCG energy expenditure-promoting effects is less clear. Studies in mice with whole-body GCGR invalidation concluded that GCG is essential for adaptive thermogenesis in BAT [<xref ref-type="bibr" rid="CR156">156</xref>]. However, Myf5 promoter-driven deletion of GCGR in BAT did not affect diet-induced obesity or glucagon-induced energy expenditure [<xref ref-type="bibr" rid="CR96">96</xref>]. These data suggested that GCGR in BAT is not essential for energy homeostasis in mice; however, thermogenically active beige adipocytes are unlikely to be affected in mice with Myf5 promoter-driven deletion of GCGR as they do not develop from a Myf5-expressing cell lineage [<xref ref-type="bibr" rid="CR157">157</xref>]. GCG can still increase energy expenditure in Ucp1-null mice [<xref ref-type="bibr" rid="CR96">96</xref>] maybe because BAT and beige adipose tissue include thermogenic cells that do not express UCP1 [<xref ref-type="bibr" rid="CR114">114</xref>]. In humans, the only available data indicate that GCG infusion increases energy expenditure but does not significantly increase BAT activity [<xref ref-type="bibr" rid="CR158">158</xref>].</p></sec><sec id="Sec25"><title>Action Mechanisms of Glucagon on BAT and WAT Browning</title><p id="Par48">Substantial evidence indicates that GCG may exert direct effects on BAT. GCGR is expressed in BAT, though at lower levels than in the liver and WAT [<xref ref-type="bibr" rid="CR96">96</xref>]. In vitro studies have shown that GCG stimulates lipolysis, lipid oxidation, and oxygen consumption in BAT explants [<xref ref-type="bibr" rid="CR96">96</xref>]. Cultured brown adipocytes treated with GCG exhibit upregulation of thermogenic genes and lipolysis and these effects are impaired when GCGR is invalidated [<xref ref-type="bibr" rid="CR96">96</xref>]. Consistent with these direct effects, GCGR activation increases intracellular cAMP, which is a major mediator of thermogenic activation in brown and beige adipocytes. GCG also exerts indirect effects by promoting BAT activation and WAT browning through the activation of hepatic FGF21 expression and release. FGF21 is a powerful inducer of thermogenic activation in adipose tissues [<xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR160">160</xref>], and results obtained from FGF21-null mice showed that FGF21 critically mediates the effects of GCG on BAT activity and WAT browning [<xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. GCG also induces the hepatic production of bile acids, which are known activators of BAT [<xref ref-type="bibr" rid="CR161">161</xref>] to further contribute to the thermogenic plasticity of adipose tissue [<xref ref-type="bibr" rid="CR103">103</xref>]. It has been proposed that action mechanism of GCG may differ by the duration of the stimulus: the acute effects of GCG are only partially dependent on BAT activation whereas the long-term effects are largely embodied by the indirect actions of GCG on BAT via FGF21 and bile acids [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par49">In summary, the experimental data strongly supports idea that GCGR agonism increases BAT and beige thermogenesis through several mechanisms while also increasing energy expenditure, although the cause-and-effect relationship of these two processes is not clear. Further research is needed to ascertain whether the GCGR agonism present in multi-receptors anti-obesity drugs under development retains these effects of single GCGR agonism (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Mechanisms of action of GCG on BAT and WAT browning. GCG acts on GCGR in brown and beige adipocytes inducing thermogenic gene expression and metabolic processes associated with active thermogenesis. In addition, GCG promotes BAT thermogenic activity and WAT browning indirectly through its action in the liver leading to the secretion of FGF21 and bile acids, known inducers of thermogenic activation of adipose tissues</p></caption><graphic id="MO5" position="float" orientation="portrait" xlink:href="13679_2025_660_Fig5_HTML.jpg"/></fig></p></sec></sec></sec><sec id="Sec26"><title>Concluding Remarks and Perspectives</title><p id="Par50">In conclusion, a growing body of experimental and clinical data indicates that changes occurring in adipose tissue may play a crucial role in mediating the beneficial effects of anti- obesity drugs based on incretin agonism. These effects seem to extend beyond the mere consequences of the fat mass reduction associated with the negative energy balance resulting from reduced food intake. Rather, the drugs appear to affect adipose tissue function either (1) indirectly, through central mechanisms that involve signalling via the peripheral nervous system to adipose and appear to be the predominant effect in GLP-1R agonism; or (2) through direct actions on adipocytes or non-adipocyte cells, such as pre-adipocytes or immune cells within the tissue. This latter mechanism seems particularly relevant for the GIPR agonism and possibly GCGR agonism actions present in the drugs currently under development. Furthermore, there is evidence that the combined GLP-1R/GIPR agonism enhances the thermogenic plasticity of adipose tissue, leading to beneficial effects on energy balance and systemic metabolism.</p><p id="Par51">For the anti-obesity drugs currently in use and under development, several open questions remain regarding their effects on adipose tissue and their broader health implications, which require further research. One important area of investigation is how various treatments influence fat depots, particularly visceral fat, and whether these treatments can fully reverse its obesity-related pro-inflammatory characteristics. Additionally, the impact of treatments on specific adipose depots, such as perivascular adipose tissue, deserves further exploration, especially in light of emerging evidence regarding the reduction of epicardial fat mass and its cardiovascular implications.</p><p id="Par52">On the other hand, a major goal in enhancing current obesity treatments is to prevent the loss of lean body mass during weight loss [<xref ref-type="bibr" rid="CR162">162</xref>]. The importance of research on the actions of incretin-based drugs in adipose tissue is not unrelated to this challenging issue, in light of the growing understanding of the cross-talk between adipose and muscle tissue through metabolic and endocrine signals [<xref ref-type="bibr" rid="CR163">163</xref>]. Enhancing the beneficial effects of incretin-based drugs on the adipose tissue secretome and its signaling to muscle may help preserve muscle mass and function. Further research is needed to advance in this field given the importance of elucidating how treatments influence the adipose tissue secretome, a key mediator of systemic inter-organ communication.</p><p id="Par53">Another crucial area of research is examining how different drugs might affect adipose tissue in a gender-specific manner, given the known sexual dimorphism in adipose tissue distribution. This could have significant implications for the prescribing of treatments.</p><p id="Par54">A further critical area of exploration will be confirming in humans the potential for treatments to induce thermogenic plasticity in adipose tissue, a process suggested by preclinical studies, and understanding how different agonists may contribute to enhancing this process.</p><p id="Par55">Lastly, the ability of incretin agonism-based drugs to restore adipose tissue to a healthy state and the persistence of their effects warrants examination. Maintaining weight loss after obesity is challenging, and evidence suggests that non-pharmacological interventions, such as food restriction and bariatric surgery, do not fully reverse obesity&#8217;s effects on adipose tissue, particularly in terms of innate immunity and mitochondrial changes in visceral fat [<xref ref-type="bibr" rid="CR164">164</xref>, <xref ref-type="bibr" rid="CR165">165</xref>]. Recent findings attribute this &#8220;obese memory&#8221; to stable obesity-driven epigenetic changes in adipocytes [<xref ref-type="bibr" rid="CR166">166</xref>]. Future research is needed to investigate whether drug-based treatments can more completely restore adipose tissue health following weight loss. Recent preclinical data suggesting that GIPR agonism promotes a &#8220;healthy metabolic memory&#8221; in adipocytes [<xref ref-type="bibr" rid="CR73">73</xref>] offers promising insights into the potential long-term efficacy of incretin-based drug treatments.</p><p id="Par56">In summary, beyond recognising the significant effects of new anti-obesity drugs in reducing weight and adipose mass, the field currently needs a new level of research to determine the specific actions and consequences of these drugs on the properties of adipose tissue. Such studies should focus not only on changes in tissue mass but, more importantly, on alterations in the biological properties of adipose tissue in treated patients. This work, which will require extensive preclinical research and studies on human cohorts undergoing treatment, could lead to a better understanding of both the drugs currently in use and those in development, and may inspire relevant improvements based on their effects on adipose tissues.</p></sec><sec id="Sec27"><title>Key references</title><p id="Par57">
<list list-type="bullet"><list-item><p id="Par58">Holst JJ. GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management. <italic toggle="yes">Nat Metab</italic>. 2024;6:1866&#8211;85</p></list-item></list>
</p><p id="Par59">
<list list-type="bullet"><list-item><p id="Par60"> This is an updated review of the current understanding of GLP-1 effects and its role in the use of GLP-1 agonists as anti-obesity drugs.</p></list-item></list>
</p><p id="Par61">
<list list-type="bullet"><list-item><p id="Par62">M&#252;ller TD, Adriaenssens A, Ahr&#233;n B, Bl&#252;her M, Birkenfeld AL, Campbell JE et al. Glucose-dependent insulinotropic polypeptide (GIP). <italic toggle="yes">Mol Metab</italic>. 2025, 95:102118</p></list-item></list>
</p><p id="Par63">
<list list-type="bullet"><list-item><p id="Par64"> Updated comprehensive review on the multifaceted nature of GIP biology and its therapeutic implications</p></list-item></list>
</p><p id="Par65">
<list list-type="bullet"><list-item><p id="Par66">Wong CK, McLean BA, Baggio LL, Koehler JA, Hammoud R, Rittig N, et al. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. <italic toggle="yes">Cell Metab.</italic> 2024;36:130-143.</p></list-item></list>
</p><p id="Par67">
<list list-type="bullet"><list-item><p id="Par68"> The central effects of GLP-1 lead to the downregulation of systemic inflammation.</p></list-item></list>
</p><p id="Par69">
<list list-type="bullet"><list-item><p id="Par70">Kusminski CM, Perez-Tilve D, M&#252;ller TD, DiMarchi RD, Tsch&#246;p MH, Scherer PE. Transforming obesity: The advancement of multi-receptor drugs. <italic toggle="yes">Cell</italic>. 2024; 187:3829-3853.</p></list-item></list>
</p><p id="Par71">
<list list-type="bullet"><list-item><p id="Par72"> This is a comprehensive review of the current knowledge on the effects of multi-receptor anti-obesity drugs and their known mechanisms of action.</p></list-item></list>
</p><p id="Par73">
<list list-type="bullet"><list-item><p id="Par74">Regmi A, Aihara E, Christe ME, Varga G, Beyer TP, Ruan X, et al. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. <italic toggle="yes">Cell Metab</italic>. 2024;36:1534-1549.</p></list-item></list>
</p><p id="Par75">
<list list-type="bullet"><list-item><p id="Par76"> Tirzepatide, due to its GIP agonist component, directly affects white adipose tissue metabolism, eliciting distinct effects depending on the organism's feeding status.</p></list-item></list>
</p><p id="Par77">
<list list-type="bullet"><list-item><p id="Par78">Yu X, Chen S, Funcke J-B, Straub LG, Pirro V, Emont MP, et al. The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice. <italic toggle="yes">Cell Metab</italic>. 2025; 37:187-204.</p></list-item></list>
</p><p id="Par79">
<list list-type="bullet"><list-item><p id="Par80"> GIP acts on white adipocytes to promote energy expenditure through a mechanism that involves a futile calcium cycle.</p></list-item></list>
</p><p id="Par81">
<list list-type="bullet"><list-item><p id="Par82">Valdecantos MP, Ruiz L, Folgueira C, Rada P, Gomez-Santos B, Solas M, et al. The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk. <italic toggle="yes">Nat Commun</italic>. 2024;15:10342</p></list-item></list>
</p><p id="Par83">
<list list-type="bullet"><list-item><p id="Par84">Glucagon agonism, when added to GLP-1 agonism, enhances weight loss by inducing energy expenditure and promoting the browning of adipose tissue.</p></list-item></list>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank the State Agency of Research of the Spanish Ministry of Science (MICIN/AEI/10.13039/50110 0011033 and FEDER, EU MCIN (grants PID2020-114112RB-I00 and PID2023-1467810-I00) and Instituto de Salud Carlos III and FEDER, EU (grant PI20/00106) for funding. M.P. is a &#8220;Ramon y Cajal&#8221; researcher (grant RYC2022-037961-I funded by the MCIN/AEI/10.13039/501100011033 and by the European Union Next Generation EU/PRTR).</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>F.V., M.P. and M.G wrote the main manuscript. M.P. prepared the Figures. All authors reviewed the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing Interests</title><p id="Par85">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><collab>NCD Risk Factor Collaboration (NCD-RisC)</collab></person-group><article-title>Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults</article-title><source>Lancet</source><year>2024</year><volume>403</volume><fpage>1027</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">38432237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(23)02750-2</pub-id><pub-id pub-id-type="pmcid">PMC7615769</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403:1027&#8211;50.<pub-id pub-id-type="pmid">38432237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(23)02750-2</pub-id><pub-id pub-id-type="pmcid">PMC7615769</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perdomo</surname><given-names>CM</given-names></name><name name-style="western"><surname>Landecho</surname><given-names>MF</given-names></name><name name-style="western"><surname>Valent&#237;</surname><given-names>V</given-names></name><name name-style="western"><surname>Moncada</surname><given-names>R</given-names></name><name name-style="western"><surname>Fr&#252;hbeck</surname><given-names>G</given-names></name></person-group><article-title>Clinical perspectives, eligibility, and success criteria for bariatric/metabolic surgery</article-title><source>Adv Exp Med Biol</source><year>2024</year><volume>1460</volume><fpage>677</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">39287869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-031-63657-8_23</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Perdomo CM, Landecho MF, Valent&#237; V, Moncada R, Fr&#252;hbeck G. Clinical perspectives, eligibility, and success criteria for bariatric/metabolic surgery. Adv Exp Med Biol. 2024;1460:677&#8211;95.<pub-id pub-id-type="pmid">39287869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-031-63657-8_23</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samms</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Kusminski</surname><given-names>CM</given-names></name></person-group><article-title>A mechanistic rationale for incretin-based therapeutics in the management of obesity</article-title><source>Annu Rev Physiol</source><year>2025</year><volume>87</volume><fpage>279</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">39546586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-physiol-022724-105443</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Samms RJ, Kusminski CM. A mechanistic rationale for incretin-based therapeutics in the management of obesity. Annu Rev Physiol. 2025;87:279&#8211;99.<pub-id pub-id-type="pmid">39546586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-physiol-022724-105443</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsen</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Tang-Christensen</surname><given-names>M</given-names></name><name name-style="western"><surname>Holst</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Orskov</surname><given-names>C</given-names></name></person-group><article-title>Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem</article-title><source>Neuroscience</source><year>1997</year><volume>77</volume><fpage>257</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">9044391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0306-4522(96)00434-4</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience. 1997;77:257&#8211;70.<pub-id pub-id-type="pmid">9044391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0306-4522(96)00434-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>SA</given-names></name><name name-style="western"><surname>Golec</surname><given-names>DP</given-names></name><name name-style="western"><surname>Hubert</surname><given-names>M</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J</given-names></name><name name-style="western"><surname>Salamon</surname><given-names>N</given-names></name><name name-style="western"><surname>Barr</surname><given-names>A</given-names></name><etal/></person-group><article-title>Human Islets contain a subpopulation of glucagon-like peptide-1 secreting &#945; cells that is increased in type 2 diabetes</article-title><source>Mol Metab</source><year>2020</year><volume>39</volume><fpage>101014</fpage><pub-id pub-id-type="pmid">32413586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2020.101014</pub-id><pub-id pub-id-type="pmcid">PMC7260680</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Campbell SA, Golec DP, Hubert M, Johnson J, Salamon N, Barr A, et al. Human Islets contain a subpopulation of glucagon-like peptide-1 secreting &#945; cells that is increased in type 2 diabetes. Mol Metab. 2020;39:101014.<pub-id pub-id-type="pmid">32413586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2020.101014</pub-id><pub-id pub-id-type="pmcid">PMC7260680</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ayala</surname><given-names>JE</given-names></name><name name-style="western"><surname>Bracy</surname><given-names>DP</given-names></name><name name-style="western"><surname>James</surname><given-names>FD</given-names></name><name name-style="western"><surname>Julien</surname><given-names>BM</given-names></name><name name-style="western"><surname>Wasserman</surname><given-names>DH</given-names></name><name name-style="western"><surname>Drucker</surname><given-names>DJ</given-names></name></person-group><article-title>The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action</article-title><source>Endocrinology</source><year>2009</year><volume>150</volume><fpage>1155</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">19008308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2008-0945</pub-id><pub-id pub-id-type="pmcid">PMC2654733</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Ayala JE, Bracy DP, James FD, Julien BM, Wasserman DH, Drucker DJ. The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology. 2009;150:1155&#8211;64.<pub-id pub-id-type="pmid">19008308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2008-0945</pub-id><pub-id pub-id-type="pmcid">PMC2654733</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holst</surname><given-names>JJ</given-names></name></person-group><article-title>GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management</article-title><source>Nat Metab</source><year>2024</year><volume>6</volume><fpage>1866</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">39160334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-024-01113-9</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Holst JJ. GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management. Nat Metab. 2024;6:1866&#8211;85.<pub-id pub-id-type="pmid">39160334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-024-01113-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nogueiras</surname><given-names>R</given-names></name><name name-style="western"><surname>Nauck</surname><given-names>MA</given-names></name><name name-style="western"><surname>Tsch&#246;p</surname><given-names>MH</given-names></name></person-group><article-title>Gut hormone co-agonists for the treatment of obesity: from bench to bedside</article-title><source>Nat Metab</source><year>2023</year><volume>5</volume><fpage>933</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">37308724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-023-00812-z</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Nogueiras R, Nauck MA, Tsch&#246;p MH. Gut hormone co-agonists for the treatment of obesity: from bench to bedside. Nat Metab. 2023;5:933&#8211;44.<pub-id pub-id-type="pmid">37308724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-023-00812-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammoud</surname><given-names>R</given-names></name><name name-style="western"><surname>Drucker</surname><given-names>DJ</given-names></name></person-group><article-title>Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1</article-title><source>Nat Rev Endocrinol</source><year>2023</year><volume>19</volume><fpage>201</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">36509857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41574-022-00783-3</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol. 2023;19:201&#8211;16.<pub-id pub-id-type="pmid">36509857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41574-022-00783-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>TD</given-names></name><name name-style="western"><surname>Adriaenssens</surname><given-names>A</given-names></name><name name-style="western"><surname>Ahr&#233;n</surname><given-names>B</given-names></name><name name-style="western"><surname>Bl&#252;her</surname><given-names>M</given-names></name><name name-style="western"><surname>Birkenfeld</surname><given-names>AL</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Glucose-dependent insulinotropic polypeptide (GIP)</article-title><source>Mol Metab</source><year>2025</year><volume>95</volume><fpage>102118</fpage><pub-id pub-id-type="pmid">40024571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2025.102118</pub-id><pub-id pub-id-type="pmcid">PMC11931254</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">M&#252;ller TD, Adriaenssens A, Ahr&#233;n B, Bl&#252;her M, Birkenfeld AL, Campbell JE, et al. Glucose-dependent insulinotropic polypeptide (GIP). Mol Metab. 2025;95:102118.<pub-id pub-id-type="pmid">40024571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2025.102118</pub-id><pub-id pub-id-type="pmcid">PMC11931254</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayendraraj</surname><given-names>A</given-names></name><name name-style="western"><surname>Rosenkilde</surname><given-names>MM</given-names></name><name name-style="western"><surname>Gasbjerg</surname><given-names>LS</given-names></name></person-group><article-title>GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation</article-title><source>Peptides (NY)</source><year>2022</year><volume>151</volume><fpage>170749</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.peptides.2022.170749</pub-id><pub-id pub-id-type="pmid">35065096</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Mayendraraj A, Rosenkilde MM, Gasbjerg LS. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation. Peptides (NY). 2022;151:170749.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.peptides.2022.170749</pub-id><pub-id pub-id-type="pmid">35065096</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drucker</surname><given-names>DJ</given-names></name></person-group><article-title>Biologic actions and therapeutic potential of the proglucagon-derived peptides</article-title><source>Nat Clin Pract Endocrinol Metab</source><year>2005</year><volume>1</volume><fpage>22</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">16929363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncpendmet0017</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab. 2005;1:22&#8211;31.<pub-id pub-id-type="pmid">16929363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncpendmet0017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#230;dersdal</surname><given-names>S</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>A</given-names></name><name name-style="western"><surname>Knop</surname><given-names>FK</given-names></name><name name-style="western"><surname>Vilsb&#248;ll</surname><given-names>T</given-names></name></person-group><article-title>Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases</article-title><source>Nat Rev Endocrinol</source><year>2023</year><volume>19</volume><fpage>321</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">36932176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41574-023-00817-4</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">H&#230;dersdal S, Andersen A, Knop FK, Vilsb&#248;ll T. Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases. Nat Rev Endocrinol. 2023;19:321&#8211;35.<pub-id pub-id-type="pmid">36932176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41574-023-00817-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jonderko</surname><given-names>G</given-names></name><name name-style="western"><surname>Jonderko</surname><given-names>K</given-names></name><name name-style="western"><surname>Go&#322;ab</surname><given-names>T</given-names></name></person-group><article-title>Effect of glucagon on gastric emptying and on postprandial gastrin and insulin release in man</article-title><source>Mater Med Pol</source><year>1989</year><volume>21</volume><fpage>92</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">2488472</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Jonderko G, Jonderko K, Go&#322;ab T. Effect of glucagon on gastric emptying and on postprandial gastrin and insulin release in man. Mater Med Pol. 1989;21:92&#8211;6.<pub-id pub-id-type="pmid">2488472</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Massadi</surname><given-names>O</given-names></name><name name-style="western"><surname>Fern&#248;</surname><given-names>J</given-names></name><name name-style="western"><surname>Di&#233;guez</surname><given-names>C</given-names></name><name name-style="western"><surname>Nogueiras</surname><given-names>R</given-names></name><name name-style="western"><surname>Qui&#241;ones</surname><given-names>M</given-names></name></person-group><article-title>Glucagon control on food intake and energy balance</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><fpage>3905</fpage><pub-id pub-id-type="pmid">31405212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20163905</pub-id><pub-id pub-id-type="pmcid">PMC6719123</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Al-Massadi O, Fern&#248; J, Di&#233;guez C, Nogueiras R, Qui&#241;ones M. Glucagon control on food intake and energy balance. Int J Mol Sci. 2019;20:3905.<pub-id pub-id-type="pmid">31405212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20163905</pub-id><pub-id pub-id-type="pmcid">PMC6719123</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleinert</surname><given-names>M</given-names></name><name name-style="western"><surname>Sachs</surname><given-names>S</given-names></name><name name-style="western"><surname>Habegger</surname><given-names>KM</given-names></name><name name-style="western"><surname>Hofmann</surname><given-names>SM</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>TD</given-names></name></person-group><article-title>Glucagon regulation of energy expenditure</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><fpage>5407</fpage><pub-id pub-id-type="pmid">31671603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20215407</pub-id><pub-id pub-id-type="pmcid">PMC6862306</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Kleinert M, Sachs S, Habegger KM, Hofmann SM, M&#252;ller TD. Glucagon regulation of energy expenditure. Int J Mol Sci. 2019;20:5407.<pub-id pub-id-type="pmid">31671603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20215407</pub-id><pub-id pub-id-type="pmcid">PMC6862306</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagberg</surname><given-names>CE</given-names></name><name name-style="western"><surname>Spalding</surname><given-names>KL</given-names></name></person-group><article-title>White adipocyte dysfunction and obesity-associated pathologies in humans</article-title><source>Nat Rev Mol Cell Biol</source><year>2024</year><volume>25</volume><fpage>270</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">38086922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-023-00680-1</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Hagberg CE, Spalding KL. White adipocyte dysfunction and obesity-associated pathologies in humans. Nat Rev Mol Cell Biol. 2024;25:270&#8211;89.<pub-id pub-id-type="pmid">38086922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-023-00680-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giralt</surname><given-names>M</given-names></name><name name-style="western"><surname>Cereijo</surname><given-names>R</given-names></name><name name-style="western"><surname>Villarroya</surname><given-names>F</given-names></name></person-group><article-title>Adipokines and the endocrine role of adipose tissues</article-title><source>Handb Exp Pharmacol</source><year>2016</year><volume>233</volume><fpage>265</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">25903415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/164_2015_6</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Giralt M, Cereijo R, Villarroya F. Adipokines and the endocrine role of adipose tissues. Handb Exp Pharmacol. 2016;233:265&#8211;82.<pub-id pub-id-type="pmid">25903415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/164_2015_6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>JE</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>TD</given-names></name><name name-style="western"><surname>Finan</surname><given-names>B</given-names></name><name name-style="western"><surname>DiMarchi</surname><given-names>RD</given-names></name><name name-style="western"><surname>Tsch&#246;p</surname><given-names>MH</given-names></name><name name-style="western"><surname>D&#8217;Alessio</surname><given-names>DA</given-names></name></person-group><article-title>GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications</article-title><source>Cell Metab</source><year>2023</year><volume>35</volume><fpage>1519</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">37591245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2023.07.010</pub-id><pub-id pub-id-type="pmcid">PMC10528201</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Campbell JE, M&#252;ller TD, Finan B, DiMarchi RD, Tsch&#246;p MH, D&#8217;Alessio DA. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications. Cell Metab. 2023;35:1519&#8211;29.<pub-id pub-id-type="pmid">37591245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2023.07.010</pub-id><pub-id pub-id-type="pmcid">PMC10528201</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilding</surname><given-names>JPH</given-names></name><name name-style="western"><surname>Batterham</surname><given-names>RL</given-names></name><name name-style="western"><surname>Calanna</surname><given-names>S</given-names></name><name name-style="western"><surname>Davies</surname><given-names>M</given-names></name><name name-style="western"><surname>Van Gaal</surname><given-names>LF</given-names></name><name name-style="western"><surname>Lingvay</surname><given-names>I</given-names></name><etal/></person-group><article-title>Once-weekly semaglutide in adults with overweight or obesity</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><fpage>989</fpage><lpage>1002</lpage><pub-id pub-id-type="pmid">33567185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2032183</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989&#8211;1002.<pub-id pub-id-type="pmid">33567185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2032183</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>DH</given-names></name><name name-style="western"><surname>Lingvay</surname><given-names>I</given-names></name><name name-style="western"><surname>Deanfield</surname><given-names>J</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>SE</given-names></name><name name-style="western"><surname>Barros</surname><given-names>E</given-names></name><name name-style="western"><surname>Burguera</surname><given-names>B</given-names></name><etal/></person-group><article-title>Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial</article-title><source>Nat Med</source><year>2024</year><volume>30</volume><fpage>2049</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">38740993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-02996-7</pub-id><pub-id pub-id-type="pmcid">PMC11271387</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30:2049&#8211;57.<pub-id pub-id-type="pmid">38740993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-02996-7</pub-id><pub-id pub-id-type="pmcid">PMC11271387</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turton</surname><given-names>MD</given-names></name><name name-style="western"><surname>O&#8217;Shea</surname><given-names>D</given-names></name><name name-style="western"><surname>Gunn</surname><given-names>I</given-names></name><name name-style="western"><surname>Beak</surname><given-names>SA</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>CM</given-names></name><name name-style="western"><surname>Meeran</surname><given-names>K</given-names></name><etal/></person-group><article-title>A role for glucagon-like peptide-1 in the central regulation of feeding</article-title><source>Nature</source><year>1996</year><volume>379</volume><fpage>69</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">8538742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/379069a0</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Turton MD, O&#8217;Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379:69&#8211;72.<pub-id pub-id-type="pmid">8538742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/379069a0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varin</surname><given-names>EM</given-names></name><name name-style="western"><surname>Mulvihill</surname><given-names>EE</given-names></name><name name-style="western"><surname>Baggio</surname><given-names>LL</given-names></name><name name-style="western"><surname>Koehler</surname><given-names>JA</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X</given-names></name><name name-style="western"><surname>Seeley</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Distinct neural sites of GLP-1R expression mediate physiological versus pharmacological control of incretin action</article-title><source>Cell Rep</source><year>2019</year><volume>27</volume><fpage>3371</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">31189118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2019.05.055</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Varin EM, Mulvihill EE, Baggio LL, Koehler JA, Cao X, Seeley RJ, et al. Distinct neural sites of GLP-1R expression mediate physiological versus Pharmacological control of incretin action. Cell Rep. 2019;27:3371&#8211;84.<pub-id pub-id-type="pmid">31189118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2019.05.055</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Argyrakopoulou</surname><given-names>G</given-names></name><name name-style="western"><surname>Gitsi</surname><given-names>E</given-names></name><name name-style="western"><surname>Konstantinidou</surname><given-names>SK</given-names></name><name name-style="western"><surname>Kokkinos</surname><given-names>A</given-names></name></person-group><article-title>The effect of obesity pharmacotherapy on body composition, including muscle mass</article-title><source>Int J Obes (Lond)</source><year>2025</year><volume>49</volume><fpage>381</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">38745020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41366-024-01533-3</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Argyrakopoulou G, Gitsi E, Konstantinidou SK, Kokkinos A. The effect of obesity pharmacotherapy on body composition, including muscle mass. Int J Obes (Lond). 2025;49:381&#8211;7.<pub-id pub-id-type="pmid">38745020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41366-024-01533-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilding</surname><given-names>JPH</given-names></name><name name-style="western"><surname>Batterham</surname><given-names>RL</given-names></name><name name-style="western"><surname>Calanna</surname><given-names>S</given-names></name><name name-style="western"><surname>Van Gaal</surname><given-names>LF</given-names></name><name name-style="western"><surname>McGowan</surname><given-names>BM</given-names></name><name name-style="western"><surname>Rosenstock</surname><given-names>J</given-names></name><etal/></person-group><article-title>Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study</article-title><source>J Endocr Soc</source><year>2021</year><volume>5</volume><fpage>A16&#8211;7</fpage></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Wilding JPH, Batterham RL, Calanna S, Van Gaal LF, McGowan BM, Rosenstock J, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. J Endocr Soc. 2021;5: A16&#8211;7.</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akoumianakis</surname><given-names>I</given-names></name><name name-style="western"><surname>Zagaliotis</surname><given-names>A</given-names></name><name name-style="western"><surname>Konstantaraki</surname><given-names>M</given-names></name><name name-style="western"><surname>Filippatos</surname><given-names>TD</given-names></name></person-group><article-title>GLP-1 analogs and regional adiposity: a systematic review and meta-analysis</article-title><source>Obes Rev</source><year>2023</year><volume>24</volume><fpage>e13574</fpage><pub-id pub-id-type="pmid">37191219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/obr.13574</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Akoumianakis I, Zagaliotis A, Konstantaraki M, Filippatos TD. GLP-1 analogs and regional adiposity: a systematic review and meta-analysis. Obes Rev. 2023;24: e13574.<pub-id pub-id-type="pmid">37191219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/obr.13574</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neeland</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Marso</surname><given-names>SP</given-names></name><name name-style="western"><surname>Ayers</surname><given-names>CR</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>B</given-names></name><name name-style="western"><surname>Oslica</surname><given-names>R</given-names></name><name name-style="western"><surname>Francis</surname><given-names>W</given-names></name><etal/></person-group><article-title>Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial</article-title><source>Lancet Diabetes Endocrinol</source><year>2021</year><volume>9</volume><fpage>595</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">34358471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(21)00179-0</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Neeland IJ, Marso SP, Ayers CR, Lewis B, Oslica R, Francis W, et al. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes Endocrinol. 2021;9:595&#8211;605.<pub-id pub-id-type="pmid">34358471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(21)00179-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Nie</surname><given-names>X</given-names></name><name name-style="western"><surname>Abudukerimu</surname><given-names>B</given-names></name><etal/></person-group><article-title>The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution</article-title><source>J Endocrinol</source><year>2019</year><volume>240</volume><fpage>271</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">30530905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/JOE-18-0374</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Zhao L, Zhu C, Lu M, Chen C, Nie X, Abudukerimu B, et al. The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution. J Endocrinol. 2019;240:271&#8211;86.<pub-id pub-id-type="pmid">30530905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/JOE-18-0374</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kissebah</surname><given-names>AH</given-names></name><name name-style="western"><surname>Krakower</surname><given-names>GR</given-names></name></person-group><article-title>Regional adiposity and morbidity</article-title><source>Physiol Rev</source><year>1994</year><volume>74</volume><fpage>761</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">7938225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.1994.74.4.761</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev. 1994;74:761&#8211;811.<pub-id pub-id-type="pmid">7938225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.1994.74.4.761</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>C</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>O</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>AE</given-names></name><name name-style="western"><surname>Killick</surname><given-names>D</given-names></name><name name-style="western"><surname>Crilly</surname><given-names>S</given-names></name><name name-style="western"><surname>Dodd</surname><given-names>JD</given-names></name><etal/></person-group><article-title>GLP-1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea</article-title><source>Obes (Silver Spring)</source><year>2024</year><volume>32</volume><fpage>2077</fpage><lpage>81</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/oby.24126</pub-id><pub-id pub-id-type="pmid">39169732</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">O&#8217;Donnell C, Ryan O, Hogan AE, Killick D, Crilly S, Dodd JD, et al. GLP-1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea. Obes (Silver Spring). 2024;32:2077&#8211;81.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/oby.24126</pub-id><pub-id pub-id-type="pmid">39169732</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pastel</surname><given-names>E</given-names></name><name name-style="western"><surname>McCulloch</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Ward</surname><given-names>R</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>S</given-names></name><name name-style="western"><surname>Gooding</surname><given-names>KM</given-names></name><name name-style="western"><surname>Shore</surname><given-names>AC</given-names></name><etal/></person-group><article-title>GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction</article-title><source>Clin Sci (Lond)</source><year>2017</year><volume>131</volume><fpage>343</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">28049736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/CS20160803</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Pastel E, McCulloch LJ, Ward R, Joshi S, Gooding KM, Shore AC, et al. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction. Clin Sci (Lond). 2017;131:343&#8211;53.<pub-id pub-id-type="pmid">28049736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/CS20160803</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simental-Mend&#237;a</surname><given-names>LE</given-names></name><name name-style="western"><surname>S&#225;nchez-Garc&#237;a</surname><given-names>A</given-names></name><name name-style="western"><surname>Linden-Torres</surname><given-names>E</given-names></name><name name-style="western"><surname>Simental-Mend&#237;a</surname><given-names>M</given-names></name></person-group><article-title>Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: a meta-analysis of randomized controlled trials</article-title><source>Br J Clin Pharmacol</source><year>2021</year><volume>87</volume><fpage>4140</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">33835520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.14855</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Simental-Mend&#237;a LE, S&#225;nchez-Garc&#237;a A, Linden-Torres E, Simental-Mend&#237;a M. Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2021;87:4140&#8211;9.<pub-id pub-id-type="pmid">33835520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.14855</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simental-Mend&#237;a</surname><given-names>LE</given-names></name><name name-style="western"><surname>S&#225;nchez-Garc&#237;a</surname><given-names>A</given-names></name><name name-style="western"><surname>Linden-Torres</surname><given-names>E</given-names></name><name name-style="western"><surname>Simental-Mend&#237;a</surname><given-names>M</given-names></name></person-group><article-title>Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: a meta-analysis of randomized controlled trials</article-title><source>Diabetes Res Clin Pract</source><year>2021</year><volume>177</volume><fpage>108899</fpage><pub-id pub-id-type="pmid">34098057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2021.108899</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Simental-Mend&#237;a LE, S&#225;nchez-Garc&#237;a A, Linden-Torres E, Simental-Mend&#237;a M. Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2021;177: 108899.<pub-id pub-id-type="pmid">34098057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2021.108899</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garvey</surname><given-names>WT</given-names></name><name name-style="western"><surname>Batterham</surname><given-names>RL</given-names></name><name name-style="western"><surname>Bhatta</surname><given-names>M</given-names></name><name name-style="western"><surname>Buscemi</surname><given-names>S</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>LN</given-names></name><name name-style="western"><surname>Frias</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><fpage>2083</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">36216945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-02026-4</pub-id><pub-id pub-id-type="pmcid">PMC9556320</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083&#8211;91.<pub-id pub-id-type="pmid">36216945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-02026-4</pub-id><pub-id pub-id-type="pmcid">PMC9556320</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iacobellis</surname><given-names>G</given-names></name><name name-style="western"><surname>Mohseni</surname><given-names>M</given-names></name><name name-style="western"><surname>Bianco</surname><given-names>SD</given-names></name><name name-style="western"><surname>Banga</surname><given-names>PK</given-names></name></person-group><article-title>Liraglutide causes large and rapid epicardial fat reduction</article-title><source>Obesity</source><year>2017</year><volume>25</volume><fpage>311</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">28124506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/oby.21718</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Iacobellis G, Mohseni M, Bianco SD, Banga PK. Liraglutide causes large and rapid epicardial fat reduction. Obesity. 2017;25:311&#8211;6.<pub-id pub-id-type="pmid">28124506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/oby.21718</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Eyk</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Paiman</surname><given-names>EHM</given-names></name><name name-style="western"><surname>Bizino</surname><given-names>MB</given-names></name><name name-style="western"><surname>de Heer</surname><given-names>P</given-names></name><name name-style="western"><surname>Geelhoed-Duijvestijn</surname><given-names>PH</given-names></name><name name-style="western"><surname>Kharagjitsingh</surname><given-names>AV</given-names></name><etal/></person-group><article-title>A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients</article-title><source>Cardiovasc Diabetol</source><year>2019</year><volume>18</volume><fpage>87</fpage><pub-id pub-id-type="pmid">31288820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12933-019-0890-5</pub-id><pub-id pub-id-type="pmcid">PMC6615254</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">van Eyk HJ, Paiman EHM, Bizino MB, de Heer P, Geelhoed-Duijvestijn PH, Kharagjitsingh AV, et al. A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients. Cardiovasc Diabetol. 2019;18: 87.<pub-id pub-id-type="pmid">31288820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12933-019-0890-5</pub-id><pub-id pub-id-type="pmcid">PMC6615254</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bizino</surname><given-names>MB</given-names></name><name name-style="western"><surname>Jazet</surname><given-names>IM</given-names></name><name name-style="western"><surname>de Heer</surname><given-names>P</given-names></name><name name-style="western"><surname>van Eyk</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Dekkers</surname><given-names>IA</given-names></name><name name-style="western"><surname>Rensen</surname><given-names>PCN</given-names></name><etal/></person-group><article-title>Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation</article-title><source>Diabetologia</source><year>2020</year><volume>63</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">31690988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-019-05021-6</pub-id><pub-id pub-id-type="pmcid">PMC6890592</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Bizino MB, Jazet IM, de Heer P, van Eyk HJ, Dekkers IA, Rensen PCN, et al. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. Diabetologia. 2020;63:65&#8211;74.<pub-id pub-id-type="pmid">31690988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-019-05021-6</pub-id><pub-id pub-id-type="pmcid">PMC6890592</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iacobellis</surname><given-names>G</given-names></name><name name-style="western"><surname>Villasante Fricke</surname><given-names>AC</given-names></name></person-group><article-title>Effects of semaglutide versus dulaglutide on epicardial fat thickness in subjects with type 2 diabetes and obesity</article-title><source>J Endocr Soc</source><year>2020</year><volume>4</volume><fpage>bvz042</fpage><pub-id pub-id-type="pmid">32190806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jendso/bvz042</pub-id><pub-id pub-id-type="pmcid">PMC7069837</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Iacobellis G, Villasante Fricke AC. Effects of semaglutide versus dulaglutide on epicardial fat thickness in subjects with type 2 diabetes and obesity. J Endocr Soc. 2020;4: bvz042.<pub-id pub-id-type="pmid">32190806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jendso/bvz042</pub-id><pub-id pub-id-type="pmcid">PMC7069837</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manubolu</surname><given-names>VS</given-names></name><name name-style="western"><surname>Lakshmanan</surname><given-names>S</given-names></name><name name-style="western"><surname>Kinninger</surname><given-names>A</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>K</given-names></name><name name-style="western"><surname>Susarla</surname><given-names>S</given-names></name><name name-style="western"><surname>Seok</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Effect of semaglutide on epicardial adipose tissue in type 2 diabetes: insights from the STOP (Semaglutide treatment effect on coronary atherosclerosis Progression) randomized trial</article-title><source>J Am Coll Cardiol</source><year>2024</year><volume>84</volume><fpage>865</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">39168573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2024.05.065</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Manubolu VS, Lakshmanan S, Kinninger A, Ahmad K, Susarla S, Seok HJ, et al. Effect of semaglutide on epicardial adipose tissue in type 2 diabetes: insights from the STOP (Semaglutide treatment effect on coronary atherosclerosis Progression) randomized trial. J Am Coll Cardiol. 2024;84:865&#8211;7.<pub-id pub-id-type="pmid">39168573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2024.05.065</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iacobellis</surname><given-names>G</given-names></name></person-group><article-title>Epicardial adipose tissue in contemporary cardiology</article-title><source>Nat Rev Cardiol</source><year>2022</year><volume>19</volume><fpage>593</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">35296869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41569-022-00679-9</pub-id><pub-id pub-id-type="pmcid">PMC8926097</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19:593&#8211;606.<pub-id pub-id-type="pmid">35296869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41569-022-00679-9</pub-id><pub-id pub-id-type="pmcid">PMC8926097</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuatrecasas</surname><given-names>G</given-names></name><name name-style="western"><surname>Calbo</surname><given-names>M</given-names></name><name name-style="western"><surname>Rossell</surname><given-names>O</given-names></name><name name-style="western"><surname>Dachs</surname><given-names>L</given-names></name><name name-style="western"><surname>Aguilar-Soler</surname><given-names>G</given-names></name><name name-style="western"><surname>Coves</surname><given-names>M-J</given-names></name><etal/></person-group><article-title>Effect of liraglutide in different abdominal fat layers measured by ultrasound: the importance of perirenal fat reduction</article-title><source>Obes Facts</source><year>2024</year><volume>17</volume><fpage>347</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">38643760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000538996</pub-id><pub-id pub-id-type="pmcid">PMC11299965</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Cuatrecasas G, Calbo M, Rossell O, Dachs L, Aguilar-Soler G, Coves M-J, et al. Effect of liraglutide in different abdominal fat layers measured by ultrasound: the importance of perirenal fat reduction. Obes Facts. 2024;17:347&#8211;54.<pub-id pub-id-type="pmid">38643760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000538996</pub-id><pub-id pub-id-type="pmcid">PMC11299965</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villarreal-Calderon</surname><given-names>JR</given-names></name><name name-style="western"><surname>Cuellar-Tamez</surname><given-names>R</given-names></name><name name-style="western"><surname>Castillo</surname><given-names>EC</given-names></name><name name-style="western"><surname>Luna-Ceron</surname><given-names>E</given-names></name><name name-style="western"><surname>Garc&#237;a-Rivas</surname><given-names>G</given-names></name><name name-style="western"><surname>Elizondo-Montemayor</surname><given-names>L</given-names></name></person-group><article-title>Metabolic shift precedes the resolution of inflammation in a cohort of patients undergoing bariatric and metabolic surgery</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><fpage>12127</fpage><pub-id pub-id-type="pmid">34108550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-91393-y</pub-id><pub-id pub-id-type="pmcid">PMC8190106</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Villarreal-Calderon JR, Cuellar-Tamez R, Castillo EC, Luna-Ceron E, Garc&#237;a-Rivas G, Elizondo-Montemayor L. Metabolic shift precedes the resolution of inflammation in a cohort of patients undergoing bariatric and metabolic surgery. Sci Rep. 2021;11:12127.<pub-id pub-id-type="pmid">34108550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-91393-y</pub-id><pub-id pub-id-type="pmcid">PMC8190106</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vendrell</surname><given-names>J</given-names></name><name name-style="western"><surname>El Bekay</surname><given-names>R</given-names></name><name name-style="western"><surname>Peral</surname><given-names>B</given-names></name><name name-style="western"><surname>Garc&#237;a-Fuentes</surname><given-names>E</given-names></name><name name-style="western"><surname>Megia</surname><given-names>A</given-names></name><name name-style="western"><surname>Macias-Gonzalez</surname><given-names>M</given-names></name><etal/></person-group><article-title>Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance</article-title><source>Endocrinology</source><year>2011</year><volume>152</volume><fpage>4072</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">21862620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2011-1070</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Vendrell J, El Bekay R, Peral B, Garc&#237;a-Fuentes E, Megia A, Macias-Gonzalez M, et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology. 2011;152:4072&#8211;9.<pub-id pub-id-type="pmid">21862620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2011-1070</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gutierrez</surname><given-names>AD</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hamidi</surname><given-names>V</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Saint Andre</surname><given-names>KB</given-names></name><name name-style="western"><surname>Riggs</surname><given-names>K</given-names></name><etal/></person-group><article-title>Anti-diabetic effects of GLP1 analogs are mediated by thermogenic interleukin-6 signaling in adipocytes</article-title><source>Cell Rep Med</source><year>2022</year><volume>3</volume><fpage>100813</fpage><pub-id pub-id-type="pmid">36384099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2022.100813</pub-id><pub-id pub-id-type="pmcid">PMC9729831</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Gutierrez AD, Gao Z, Hamidi V, Zhu L, Saint Andre KB, Riggs K, et al. Anti-diabetic effects of GLP1 analogs are mediated by thermogenic interleukin-6 signaling in adipocytes. Cell Rep Med. 2022;3: 100813.<pub-id pub-id-type="pmid">36384099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2022.100813</pub-id><pub-id pub-id-type="pmcid">PMC9729831</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drucker</surname><given-names>DJ</given-names></name></person-group><article-title>The ascending GLP-1 road from clinical safety to reduction of cardiovascular complications</article-title><source>Diabetes</source><year>2018</year><volume>67</volume><fpage>1710</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">30135132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dbi18-0008</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Drucker DJ. The ascending GLP-1 road from clinical safety to reduction of cardiovascular complications. Diabetes. 2018;67:1710&#8211;9.<pub-id pub-id-type="pmid">30135132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dbi18-0008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>A</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>JRD</given-names></name><name name-style="western"><surname>Chhabra</surname><given-names>G</given-names></name><name name-style="western"><surname>Krishna</surname><given-names>A</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>A</given-names></name></person-group><article-title>Liraglutide modulates adipokine expression during adipogenesis, ameliorating obesity, and polycystic ovary syndrome in mice</article-title><source>Endocrine</source><year>2019</year><volume>64</volume><fpage>349</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">30904998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12020-019-01891-3</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Singh A, Fernandes JRD, Chhabra G, Krishna A, Banerjee A. Liraglutide modulates adipokine expression during adipogenesis, ameliorating obesity, and polycystic ovary syndrome in mice. Endocrine. 2019;64:349&#8211;66.<pub-id pub-id-type="pmid">30904998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12020-019-01891-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El Bekay</surname><given-names>R</given-names></name><name name-style="western"><surname>Co&#237;n-Arag&#252;ez</surname><given-names>L</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Garc&#237;a</surname><given-names>D</given-names></name><name name-style="western"><surname>Oliva-Olivera</surname><given-names>W</given-names></name><name name-style="western"><surname>Bernal-L&#243;pez</surname><given-names>R</given-names></name><name name-style="western"><surname>Clemente-Postigo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes</article-title><source>Br J Pharmacol</source><year>2016</year><volume>173</volume><fpage>1820</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">26993859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bph.13481</pub-id><pub-id pub-id-type="pmcid">PMC4867741</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">El Bekay R, Co&#237;n-Arag&#252;ez L, Fern&#225;ndez-Garc&#237;a D, Oliva-Olivera W, Bernal-L&#243;pez R, Clemente-Postigo M, et al. Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes. Br J Pharmacol. 2016;173:1820&#8211;34.<pub-id pub-id-type="pmid">26993859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bph.13481</pub-id><pub-id pub-id-type="pmcid">PMC4867741</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Challa</surname><given-names>TD</given-names></name><name name-style="western"><surname>Beaton</surname><given-names>N</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>M</given-names></name><name name-style="western"><surname>Rudofsky</surname><given-names>G</given-names></name><name name-style="western"><surname>Langhans</surname><given-names>W</given-names></name><name name-style="western"><surname>Wolfrum</surname><given-names>C</given-names></name></person-group><article-title>Regulation of adipocyte formation by GLP-1/GLP-1R signaling</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><fpage>6421</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">22207759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M111.310342</pub-id><pub-id pub-id-type="pmcid">PMC3307265</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Challa TD, Beaton N, Arnold M, Rudofsky G, Langhans W, Wolfrum C. Regulation of adipocyte formation by GLP-1/GLP-1R signaling. J Biol Chem. 2012;287:6421&#8211;30.<pub-id pub-id-type="pmid">22207759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M111.310342</pub-id><pub-id pub-id-type="pmcid">PMC3307265</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>Y-S</given-names></name><name name-style="western"><surname>Park</surname><given-names>M-S</given-names></name><name name-style="western"><surname>Choung</surname><given-names>J-S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S-S</given-names></name><name name-style="western"><surname>Oh</surname><given-names>H-H</given-names></name><name name-style="western"><surname>Choi</surname><given-names>C-S</given-names></name><etal/></person-group><article-title>Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes</article-title><source>Diabetologia</source><year>2012</year><volume>55</volume><fpage>2456</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">22722451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-012-2592-3</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Lee Y-S, Park M-S, Choung J-S, Kim S-S, Oh H-H, Choi C-S, et al. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia. 2012;55:2456&#8211;68.<pub-id pub-id-type="pmid">22722451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-012-2592-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Barra</surname><given-names>C</given-names></name><name name-style="western"><surname>Khalil</surname><given-names>M</given-names></name><name name-style="western"><surname>Mat</surname><given-names>A</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>C</given-names></name><name name-style="western"><surname>Shaamile</surname><given-names>F</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>K</given-names></name><etal/></person-group><article-title>Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function</article-title><source>Obes (Silver Spring)</source><year>2023</year><volume>31</volume><fpage>1787</fpage><lpage>97</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/oby.23772</pub-id><pub-id pub-id-type="pmid">37157931</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">De Barra C, Khalil M, Mat A, O&#8217;Donnell C, Shaamile F, Brennan K, et al. Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function. Obes (Silver Spring). 2023;31:1787&#8211;97.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/oby.23772</pub-id><pub-id pub-id-type="pmid">37157931</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>CK</given-names></name><name name-style="western"><surname>McLean</surname><given-names>BA</given-names></name><name name-style="western"><surname>Baggio</surname><given-names>LL</given-names></name><name name-style="western"><surname>Koehler</surname><given-names>JA</given-names></name><name name-style="western"><surname>Hammoud</surname><given-names>R</given-names></name><name name-style="western"><surname>Rittig</surname><given-names>N</given-names></name><etal/></person-group><article-title>Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation</article-title><source>Cell Metab</source><year>2024</year><volume>36</volume><fpage>130</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">38113888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2023.11.009</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Wong CK, McLean BA, Baggio LL, Koehler JA, Hammoud R, Rittig N, et al. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. Cell Metab. 2024;36:130&#8211;43.<pub-id pub-id-type="pmid">38113888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2023.11.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyawaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ban</surname><given-names>N</given-names></name><name name-style="western"><surname>Ihara</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tsukiyama</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><etal/></person-group><article-title>Inhibition of gastric inhibitory polypeptide signaling prevents obesity</article-title><source>Nat Med</source><year>2002</year><volume>8</volume><fpage>738</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">12068290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm727</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;8:738&#8211;42.<pub-id pub-id-type="pmid">12068290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm727</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Novikoff</surname><given-names>A</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>TD</given-names></name></person-group><article-title>Antagonizing GIPR adds fire to the GLP-1R flame</article-title><source>Trends Endocrinol Metab</source><year>2024</year><volume>35</volume><fpage>566</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">38763780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tem.2024.04.016</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Novikoff A, M&#252;ller TD. Antagonizing GIPR adds fire to the GLP-1R flame. Trends Endocrinol Metab. 2024;35:566&#8211;8.<pub-id pub-id-type="pmid">38763780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tem.2024.04.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>V&#233;niant</surname><given-names>MM</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S-C</given-names></name><name name-style="western"><surname>Atangan</surname><given-names>L</given-names></name><name name-style="western"><surname>Komorowski</surname><given-names>R</given-names></name><name name-style="western"><surname>Stanislaus</surname><given-names>S</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings</article-title><source>Nat Metab</source><year>2024</year><volume>6</volume><fpage>290</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">38316982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-023-00966-w</pub-id><pub-id pub-id-type="pmcid">PMC10896721</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">V&#233;niant MM, Lu S-C, Atangan L, Komorowski R, Stanislaus S, Cheng Y, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024;6:290&#8211;303.<pub-id pub-id-type="pmid">38316982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-023-00966-w</pub-id><pub-id pub-id-type="pmcid">PMC10896721</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Goodwin Cartwright</surname><given-names>BM</given-names></name><name name-style="western"><surname>Gratzl</surname><given-names>S</given-names></name><name name-style="western"><surname>Brar</surname><given-names>R</given-names></name><name name-style="western"><surname>Baker</surname><given-names>C</given-names></name><name name-style="western"><surname>Gluckman</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity</article-title><source>JAMA Intern Med</source><year>2024</year><volume>184</volume><fpage>1056</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">38976257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2024.2525</pub-id><pub-id pub-id-type="pmcid">PMC11231910</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024;184:1056&#8211;64.<pub-id pub-id-type="pmid">38976257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2024.2525</pub-id><pub-id pub-id-type="pmcid">PMC11231910</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kusminski</surname><given-names>CM</given-names></name><name name-style="western"><surname>Perez-Tilve</surname><given-names>D</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>TD</given-names></name><name name-style="western"><surname>DiMarchi</surname><given-names>RD</given-names></name><name name-style="western"><surname>Tsch&#246;p</surname><given-names>MH</given-names></name><name name-style="western"><surname>Scherer</surname><given-names>PE</given-names></name></person-group><article-title>Transforming obesity: the advancement of multi-receptor drugs</article-title><source>Cell</source><year>2024</year><volume>187</volume><fpage>3829</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">39059360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2024.06.003</pub-id><pub-id pub-id-type="pmcid">PMC11286204</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Kusminski CM, Perez-Tilve D, M&#252;ller TD, DiMarchi RD, Tsch&#246;p MH, Scherer PE. Transforming obesity: the advancement of multi-receptor drugs. Cell. 2024;187:3829&#8211;53.<pub-id pub-id-type="pmid">39059360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2024.06.003</pub-id><pub-id pub-id-type="pmcid">PMC11286204</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finan</surname><given-names>B</given-names></name><name name-style="western"><surname>Ma</surname><given-names>T</given-names></name><name name-style="western"><surname>Ottaway</surname><given-names>N</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>TD</given-names></name><name name-style="western"><surname>Habegger</surname><given-names>KM</given-names></name><name name-style="western"><surname>Heppner</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans</article-title><source>Sci Transl Med</source><year>2013</year><volume>5</volume><fpage>209ra151</fpage><pub-id pub-id-type="pmid">24174327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3007218</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Finan B, Ma T, Ottaway N, M&#252;ller TD, Habegger KM, Heppner KM, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5: 209ra151.<pub-id pub-id-type="pmid">24174327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3007218</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coskun</surname><given-names>T</given-names></name><name name-style="western"><surname>Sloop</surname><given-names>KW</given-names></name><name name-style="western"><surname>Loghin</surname><given-names>C</given-names></name><name name-style="western"><surname>Alsina-Fernandez</surname><given-names>J</given-names></name><name name-style="western"><surname>Urva</surname><given-names>S</given-names></name><name name-style="western"><surname>Bokvist</surname><given-names>KB</given-names></name><etal/></person-group><article-title>LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept</article-title><source>Mol Metab</source><year>2018</year><volume>18</volume><fpage>3</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">30473097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2018.09.009</pub-id><pub-id pub-id-type="pmcid">PMC6308032</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3&#8211;14.<pub-id pub-id-type="pmid">30473097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2018.09.009</pub-id><pub-id pub-id-type="pmcid">PMC6308032</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Delessa</surname><given-names>CT</given-names></name><name name-style="western"><surname>Augustin</surname><given-names>R</given-names></name><name name-style="western"><surname>Bakhti</surname><given-names>M</given-names></name><name name-style="western"><surname>Colld&#233;n</surname><given-names>G</given-names></name><name name-style="western"><surname>Drucker</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling</article-title><source>Cell Metab</source><year>2021</year><volume>33</volume><fpage>833</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">33571454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2021.01.015</pub-id><pub-id pub-id-type="pmcid">PMC8035082</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Zhang Q, Delessa CT, Augustin R, Bakhti M, Colld&#233;n G, Drucker DJ, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab. 2021;33:833&#8211;44.<pub-id pub-id-type="pmid">33571454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2021.01.015</pub-id><pub-id pub-id-type="pmcid">PMC8035082</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liskiewicz</surname><given-names>A</given-names></name><name name-style="western"><surname>Khalil</surname><given-names>A</given-names></name><name name-style="western"><surname>Liskiewicz</surname><given-names>D</given-names></name><name name-style="western"><surname>Novikoff</surname><given-names>A</given-names></name><name name-style="western"><surname>Grandl</surname><given-names>G</given-names></name><name name-style="western"><surname>Maity-Kumar</surname><given-names>G</given-names></name><etal/></person-group><article-title>Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice</article-title><source>Nat Metab</source><year>2023</year><volume>5</volume><fpage>2075</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">37946085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-023-00931-7</pub-id><pub-id pub-id-type="pmcid">PMC10730394</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Liskiewicz A, Khalil A, Liskiewicz D, Novikoff A, Grandl G, Maity-Kumar G, et al. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice. Nat Metab. 2023;5:2075&#8211;85.<pub-id pub-id-type="pmid">37946085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-023-00931-7</pub-id><pub-id pub-id-type="pmcid">PMC10730394</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>MK</given-names></name><name name-style="western"><surname>Nikooienejad</surname><given-names>A</given-names></name><name name-style="western"><surname>Bray</surname><given-names>R</given-names></name><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J</given-names></name><name name-style="western"><surname>Duffin</surname><given-names>K</given-names></name><etal/></person-group><article-title>Dual GIP and GLP-1 receptor agonist tirzepatide improves Beta-cell function and insulin sensitivity in type 2 diabetes</article-title><source>J Clin Endocrinol Metab</source><year>2021</year><volume>106</volume><fpage>388</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">33236115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgaa863</pub-id><pub-id pub-id-type="pmcid">PMC7823251</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves Beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106:388&#8211;96.<pub-id pub-id-type="pmid">33236115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgaa863</pub-id><pub-id pub-id-type="pmcid">PMC7823251</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fonseca</surname><given-names>VA</given-names></name><name name-style="western"><surname>Capehorn</surname><given-names>MS</given-names></name><name name-style="western"><surname>Garg</surname><given-names>SK</given-names></name><name name-style="western"><surname>J&#243;dar Gimeno</surname><given-names>E</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>OH</given-names></name><name name-style="western"><surname>Holst</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide</article-title><source>J Clin Endocrinol Metab</source><year>2019</year><volume>104</volume><fpage>4078</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">30938762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2018-02685</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Fonseca VA, Capehorn MS, Garg SK, J&#243;dar Gimeno E, Hansen OH, Holst AG, et al. Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide. J Clin Endocrinol Metab. 2019;104:4078&#8211;86.<pub-id pub-id-type="pmid">30938762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2018-02685</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rochira</surname><given-names>V</given-names></name><name name-style="western"><surname>Greco</surname><given-names>C</given-names></name><name name-style="western"><surname>Boni</surname><given-names>S</given-names></name><name name-style="western"><surname>Costantino</surname><given-names>F</given-names></name><name name-style="western"><surname>Dalla Valentina</surname><given-names>L</given-names></name><name name-style="western"><surname>Zanni</surname><given-names>E</given-names></name><etal/></person-group><article-title>The effect of Tirzepatide on body composition in people with overweight and obesity: a systematic review of randomized, controlled studies</article-title><source>Diseases</source><year>2024</year><volume>12</volume><fpage>204</fpage><pub-id pub-id-type="pmid">39329873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diseases12090204</pub-id><pub-id pub-id-type="pmcid">PMC11431103</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Rochira V, Greco C, Boni S, Costantino F, Dalla Valentina L, Zanni E, et al. The effect of Tirzepatide on body composition in people with overweight and obesity: a systematic review of randomized, controlled studies. Diseases. 2024;12: 204.<pub-id pub-id-type="pmid">39329873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diseases12090204</pub-id><pub-id pub-id-type="pmcid">PMC11431103</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cariou</surname><given-names>B</given-names></name><name name-style="western"><surname>Linge</surname><given-names>J</given-names></name><name name-style="western"><surname>Neeland</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Dahlqvist Leinhard</surname><given-names>O</given-names></name><name name-style="western"><surname>Petersson</surname><given-names>M</given-names></name><name name-style="western"><surname>Fern&#225;ndez Land&#243;</surname><given-names>L</given-names></name><etal/></person-group><article-title>Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes</article-title><source>Diabetes Obes Metab</source><year>2024</year><volume>26</volume><fpage>2446</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">38528819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.15566</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Cariou B, Linge J, Neeland IJ, Dahlqvist Leinhard O, Petersson M, Fern&#225;ndez Land&#243; L, et al. Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes. Diabetes Obes Metab. 2024;26:2446&#8211;55.<pub-id pub-id-type="pmid">38528819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.15566</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gastaldelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Cusi</surname><given-names>K</given-names></name><name name-style="western"><surname>Fern&#225;ndez Land&#243;</surname><given-names>L</given-names></name><name name-style="western"><surname>Bray</surname><given-names>R</given-names></name><name name-style="western"><surname>Brouwers</surname><given-names>B</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>&#193;</given-names></name></person-group><article-title>Effect of Tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial</article-title><source>Lancet Diabetes Endocrinol</source><year>2022</year><volume>10</volume><fpage>393</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">35468325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(22)00070-5</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Gastaldelli A, Cusi K, Fern&#225;ndez Land&#243; L, Bray R, Brouwers B, Rodr&#237;guez &#193;. Effect of Tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10:393&#8211;406.<pub-id pub-id-type="pmid">35468325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(22)00070-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beaudry</surname><given-names>JL</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>KD</given-names></name><name name-style="western"><surname>Varin</surname><given-names>EM</given-names></name><name name-style="western"><surname>Baggio</surname><given-names>LL</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X</given-names></name><name name-style="western"><surname>Mulvihill</surname><given-names>EE</given-names></name><etal/></person-group><article-title>Physiological roles of the GIP receptor in murine brown adipose tissue</article-title><source>Mol Metab</source><year>2019</year><volume>28</volume><fpage>14</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">31451430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2019.08.006</pub-id><pub-id pub-id-type="pmcid">PMC6822254</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Beaudry JL, Kaur KD, Varin EM, Baggio LL, Cao X, Mulvihill EE, et al. Physiological roles of the GIP receptor in murine brown adipose tissue. Mol Metab. 2019;28:14&#8211;25.<pub-id pub-id-type="pmid">31451430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2019.08.006</pub-id><pub-id pub-id-type="pmcid">PMC6822254</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rudovich</surname><given-names>N</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>S</given-names></name><name name-style="western"><surname>Engeli</surname><given-names>S</given-names></name><name name-style="western"><surname>Osterhoff</surname><given-names>M</given-names></name><name name-style="western"><surname>G&#246;gebakan</surname><given-names>O</given-names></name><name name-style="western"><surname>Bluher</surname><given-names>M</given-names></name><etal/></person-group><article-title>GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women</article-title><source>Regul Pept</source><year>2007</year><volume>142</volume><fpage>138</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">17395281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.regpep.2007.02.006</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Rudovich N, Kaiser S, Engeli S, Osterhoff M, G&#246;gebakan O, Bluher M, et al. GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women. Regul Pept. 2007;142:138&#8211;45.<pub-id pub-id-type="pmid">17395281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.regpep.2007.02.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>JE</given-names></name><name name-style="western"><surname>Beaudry</surname><given-names>JL</given-names></name><name name-style="western"><surname>Svendsen</surname><given-names>B</given-names></name><name name-style="western"><surname>Baggio</surname><given-names>LL</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>AN</given-names></name><name name-style="western"><surname>Ussher</surname><given-names>JR</given-names></name><etal/></person-group><article-title>GIPR is predominantly localized to nonadipocyte cell types within white adipose tissue</article-title><source>Diabetes</source><year>2022</year><volume>71</volume><issue>5</issue><fpage>1115</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">35192688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db21-1166</pub-id><pub-id pub-id-type="pmcid">PMC7612781</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Campbell JE, Beaudry JL, Svendsen B, Baggio LL, Gordon AN, Ussher JR, et al. GIPR is predominantly localized to nonadipocyte cell types within white adipose tissue. Diabetes. 2022;71(5):1115&#8211;27.<pub-id pub-id-type="pmid">35192688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db21-1166</pub-id><pub-id pub-id-type="pmcid">PMC7612781</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Regmi</surname><given-names>A</given-names></name><name name-style="western"><surname>Aihara</surname><given-names>E</given-names></name><name name-style="western"><surname>Christe</surname><given-names>ME</given-names></name><name name-style="western"><surname>Varga</surname><given-names>G</given-names></name><name name-style="western"><surname>Beyer</surname><given-names>TP</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>X</given-names></name><etal/></person-group><article-title>Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor</article-title><source>Cell Metab</source><year>2024</year><volume>36</volume><fpage>1534</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">38878772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2024.05.010</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Regmi A, Aihara E, Christe ME, Varga G, Beyer TP, Ruan X, et al. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell Metab. 2024;36:1534&#8211;49.<pub-id pub-id-type="pmid">38878772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2024.05.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weaver</surname><given-names>RE</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>D</given-names></name><name name-style="western"><surname>Wabitsch</surname><given-names>M</given-names></name><name name-style="western"><surname>Grant</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Balmforth</surname><given-names>AJ</given-names></name></person-group><article-title>Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model</article-title><source>Int J Obes (Lond)</source><year>2008</year><volume>32</volume><fpage>1705</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">18779825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ijo.2008.148</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Weaver RE, Donnelly D, Wabitsch M, Grant PJ, Balmforth AJ. Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model. Int J Obes (Lond). 2008;32:1705&#8211;11.<pub-id pub-id-type="pmid">18779825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ijo.2008.148</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohammad</surname><given-names>S</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>LS</given-names></name><name name-style="western"><surname>Buck</surname><given-names>J</given-names></name><name name-style="western"><surname>Levin</surname><given-names>LR</given-names></name><name name-style="western"><surname>Rubino</surname><given-names>F</given-names></name><name name-style="western"><surname>McGraw</surname><given-names>TE</given-names></name></person-group><article-title>Gastric inhibitory peptide controls adipose insulin sensitivity via activation of cAMP-response element-binding protein and p110&#946; isoform of phosphatidylinositol 3-kinase</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>43062</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">22027830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M111.289009</pub-id><pub-id pub-id-type="pmcid">PMC3234864</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Mohammad S, Ramos LS, Buck J, Levin LR, Rubino F, McGraw TE. Gastric inhibitory peptide controls adipose insulin sensitivity via activation of cAMP-response element-binding protein and p110&#946; isoform of phosphatidylinositol 3-kinase. J Biol Chem. 2011;286:43062&#8211;70.<pub-id pub-id-type="pmid">22027830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M111.289009</pub-id><pub-id pub-id-type="pmcid">PMC3234864</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>DH</given-names></name><name name-style="western"><surname>Getty-Kaushik</surname><given-names>L</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>E</given-names></name><name name-style="western"><surname>Simon</surname><given-names>J</given-names></name><name name-style="western"><surname>Corkey</surname><given-names>BE</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>MM</given-names></name></person-group><article-title>Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation</article-title><source>Gastroenterology</source><year>2007</year><volume>133</volume><fpage>1796</fpage><lpage>805</lpage><pub-id pub-id-type="pmid">18054552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2007.09.005</pub-id><pub-id pub-id-type="pmcid">PMC2185546</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Song DH, Getty-Kaushik L, Tseng E, Simon J, Corkey BE, Wolfe MM. Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation. Gastroenterology. 2007;133:1796&#8211;805.<pub-id pub-id-type="pmid">18054552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2007.09.005</pub-id><pub-id pub-id-type="pmcid">PMC2185546</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Funcke</surname><given-names>J-B</given-names></name><name name-style="western"><surname>Straub</surname><given-names>LG</given-names></name><name name-style="western"><surname>Pirro</surname><given-names>V</given-names></name><name name-style="western"><surname>Emont</surname><given-names>MP</given-names></name><etal/></person-group><article-title>The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice</article-title><source>Cell Metab</source><year>2025</year><volume>37</volume><fpage>187</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">39642881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2024.11.003</pub-id><pub-id pub-id-type="pmcid">PMC11711001</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Yu X, Chen S, Funcke J-B, Straub LG, Pirro V, Emont MP, et al. The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice. Cell Metab. 2025;37:187&#8211;204.<pub-id pub-id-type="pmid">39642881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2024.11.003</pub-id><pub-id pub-id-type="pmcid">PMC11711001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><mixed-citation publication-type="other">Samms RJ, Christe ME, Collins K, Al, Pirro V, Droz BA, Holland AK et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest. 2021;131:e146353.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI146353</pub-id><pub-id pub-id-type="pmcid">PMC8203452</pub-id><pub-id pub-id-type="pmid">34003802</pub-id></mixed-citation></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McIntosh</surname><given-names>CH</given-names></name><name name-style="western"><surname>Bremsak</surname><given-names>I</given-names></name><name name-style="western"><surname>Lynn</surname><given-names>FC</given-names></name><name name-style="western"><surname>Gill</surname><given-names>R</given-names></name><name name-style="western"><surname>Hinke</surname><given-names>SA</given-names></name><name name-style="western"><surname>Gelling</surname><given-names>R</given-names></name><etal/></person-group><article-title>Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: wortmannin-sensitive Inhibition by insulin</article-title><source>Endocrinology</source><year>1999</year><volume>140</volume><fpage>398</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">9886851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/endo.140.1.6464</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">McIntosh CH, Bremsak I, Lynn FC, Gill R, Hinke SA, Gelling R, et al. Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: wortmannin-sensitive Inhibition by insulin. Endocrinology. 1999;140:398&#8211;404.<pub-id pub-id-type="pmid">9886851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/endo.140.1.6464</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S-J</given-names></name><name name-style="western"><surname>Nian</surname><given-names>C</given-names></name><name name-style="western"><surname>McIntosh</surname><given-names>CHS</given-names></name></person-group><article-title>Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>8557</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">17244606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M609088200</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Kim S-J, Nian C, McIntosh CHS. Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade. J Biol Chem. 2007;282:8557&#8211;67.<pub-id pub-id-type="pmid">17244606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M609088200</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S-J</given-names></name><name name-style="western"><surname>Nian</surname><given-names>C</given-names></name><name name-style="western"><surname>McIntosh</surname><given-names>CHS</given-names></name></person-group><article-title>GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene</article-title><source>J Lipid Res</source><year>2010</year><volume>51</volume><fpage>3145</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">20693566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1194/jlr.M006841</pub-id><pub-id pub-id-type="pmcid">PMC2952555</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Kim S-J, Nian C, McIntosh CHS. GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene. J Lipid Res. 2010;51:3145&#8211;57.<pub-id pub-id-type="pmid">20693566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1194/jlr.M006841</pub-id><pub-id pub-id-type="pmcid">PMC2952555</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Getty-Kaushik</surname><given-names>L</given-names></name><name name-style="western"><surname>Song</surname><given-names>DH</given-names></name><name name-style="western"><surname>Boylan</surname><given-names>MO</given-names></name><name name-style="western"><surname>Corkey</surname><given-names>BE</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>MM</given-names></name></person-group><article-title>Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification</article-title><source>Obesity</source><year>2006</year><volume>14</volume><fpage>1124</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">16899793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/oby.2006.129</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Getty-Kaushik L, Song DH, Boylan MO, Corkey BE, Wolfe MM. Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification. Obesity. 2006;14:1124&#8211;31.<pub-id pub-id-type="pmid">16899793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/oby.2006.129</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asmar</surname><given-names>M</given-names></name><name name-style="western"><surname>Simonsen</surname><given-names>L</given-names></name><name name-style="western"><surname>Madsbad</surname><given-names>S</given-names></name><name name-style="western"><surname>Stallknecht</surname><given-names>B</given-names></name><name name-style="western"><surname>Holst</surname><given-names>JJ</given-names></name><name name-style="western"><surname>B&#252;low</surname><given-names>J</given-names></name></person-group><article-title>Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans</article-title><source>Diabetes</source><year>2010</year><volume>59</volume><fpage>2160</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">20547981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db10-0098</pub-id><pub-id pub-id-type="pmcid">PMC2927937</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Asmar M, Simonsen L, Madsbad S, Stallknecht B, Holst JJ, B&#252;low J. Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans. Diabetes. 2010;59:2160&#8211;3.<pub-id pub-id-type="pmid">20547981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db10-0098</pub-id><pub-id pub-id-type="pmcid">PMC2927937</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samms</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Coghlan</surname><given-names>MP</given-names></name><name name-style="western"><surname>Sloop</surname><given-names>KW</given-names></name></person-group><article-title>How may GIP enhance the therapeutic efficacy of GLP-1?</article-title><source>Trends Endocrinol Metab</source><year>2020</year><volume>31</volume><fpage>410</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">32396843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tem.2020.02.006</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31:410&#8211;21.<pub-id pub-id-type="pmid">32396843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tem.2020.02.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Za&#239;mia</surname><given-names>N</given-names></name><name name-style="western"><surname>Obeid</surname><given-names>J</given-names></name><name name-style="western"><surname>Varrault</surname><given-names>A</given-names></name><name name-style="western"><surname>Sabatier</surname><given-names>J</given-names></name><name name-style="western"><surname>Broca</surname><given-names>C</given-names></name><name name-style="western"><surname>Gilon</surname><given-names>P</given-names></name><etal/></person-group><article-title>GLP-1 and GIP receptors signal through distinct &#946;-arrestin 2-dependent pathways to regulate pancreatic &#946; cell function</article-title><source>Cell Rep</source><year>2023</year><volume>42</volume><fpage>113326</fpage><pub-id pub-id-type="pmid">37897727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2023.113326</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Za&#239;mia N, Obeid J, Varrault A, Sabatier J, Broca C, Gilon P, et al. GLP-1 and GIP receptors signal through distinct &#946;-arrestin 2-dependent pathways to regulate pancreatic &#946; cell function. Cell Rep. 2023;42: 113326.<pub-id pub-id-type="pmid">37897727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2023.113326</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kizilkaya</surname><given-names>HS</given-names></name><name name-style="western"><surname>S&#248;rensen</surname><given-names>KV</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>JS</given-names></name><name name-style="western"><surname>Lindquist</surname><given-names>P</given-names></name><name name-style="western"><surname>Douros</surname><given-names>JD</given-names></name><name name-style="western"><surname>Bork-Jensen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Characterization of genetic variants of GIPR reveals a contribution of &#946;-arrestin to metabolic phenotypes</article-title><source>Nat Metab</source><year>2024</year><volume>6</volume><fpage>1268</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">38871982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-024-01061-4</pub-id><pub-id pub-id-type="pmcid">PMC11272584</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Kizilkaya HS, S&#248;rensen KV, Madsen JS, Lindquist P, Douros JD, Bork-Jensen J, et al. Characterization of genetic variants of GIPR reveals a contribution of &#946;-arrestin to metabolic phenotypes. Nat Metab. 2024;6:1268&#8211;81.<pub-id pub-id-type="pmid">38871982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-024-01061-4</pub-id><pub-id pub-id-type="pmcid">PMC11272584</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willard</surname><given-names>FS</given-names></name><name name-style="western"><surname>Douros</surname><given-names>JD</given-names></name><name name-style="western"><surname>Gabe</surname><given-names>MB</given-names></name><name name-style="western"><surname>Showalter</surname><given-names>AD</given-names></name><name name-style="western"><surname>Wainscott</surname><given-names>DB</given-names></name><name name-style="western"><surname>Suter</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist</article-title><source>JCI Insight</source><year>2020</year><volume>5</volume><fpage>e140532</fpage><pub-id pub-id-type="pmid">32730231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.140532</pub-id><pub-id pub-id-type="pmcid">PMC7526454</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5: e140532.<pub-id pub-id-type="pmid">32730231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.140532</pub-id><pub-id pub-id-type="pmcid">PMC7526454</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ikeda</surname><given-names>K</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yoneshiro</surname><given-names>T</given-names></name><name name-style="western"><surname>Camporez</surname><given-names>JP</given-names></name><name name-style="western"><surname>Maki</surname><given-names>H</given-names></name><name name-style="western"><surname>Homma</surname><given-names>M</given-names></name><etal/></person-group><article-title>UCP1-independent signaling involving SERCA2b-mediated calcium cycling regulates beige fat thermogenesis and systemic glucose homeostasis</article-title><source>Nat Med</source><year>2017</year><volume>23</volume><fpage>1454</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">29131158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.4429</pub-id><pub-id pub-id-type="pmcid">PMC5727902</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Ikeda K, Kang Q, Yoneshiro T, Camporez JP, Maki H, Homma M, et al. UCP1-independent signaling involving SERCA2b-mediated calcium cycling regulates beige fat thermogenesis and systemic glucose homeostasis. Nat Med. 2017;23:1454&#8211;65.<pub-id pub-id-type="pmid">29131158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.4429</pub-id><pub-id pub-id-type="pmcid">PMC5727902</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Auger</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Fujimoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>K</given-names></name><name name-style="western"><surname>Yook</surname><given-names>JS</given-names></name><name name-style="western"><surname>O&#8217;Leary</surname><given-names>TR</given-names></name><etal/></person-group><article-title>Identification of a molecular resistor that controls UCP1-independent Ca2&#8201;+&#8201;cycling thermogenesis in adipose tissue</article-title><source>Cell Metab</source><year>2025</year><volume>37</volume><fpage>1311</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">40199326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2025.03.009</pub-id><pub-id pub-id-type="pmcid">PMC12137002</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Auger C, Li M, Fujimoto M, Ikeda K, Yook JS, O&#8217;Leary TR, et al. Identification of a molecular resistor that controls UCP1-independent Ca2&#8201;+&#8201;cycling thermogenesis in adipose tissue. Cell Metab. 2025;37:1311&#8211;25.<pub-id pub-id-type="pmid">40199326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2025.03.009</pub-id><pub-id pub-id-type="pmcid">PMC12137002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Concei&#231;&#227;o-Furber</surname><given-names>E</given-names></name><name name-style="western"><surname>Coskun</surname><given-names>T</given-names></name><name name-style="western"><surname>Sloop</surname><given-names>KW</given-names></name><name name-style="western"><surname>Samms</surname><given-names>RJ</given-names></name></person-group><article-title>Is glucagon receptor activation the thermogenic solution for treating obesity??</article-title><source>Front Endocrinol (Lausanne)</source><year>2022</year><volume>13</volume><fpage>868037</fpage><pub-id pub-id-type="pmid">35547006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2022.868037</pub-id><pub-id pub-id-type="pmcid">PMC9081793</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Concei&#231;&#227;o-Furber E, Coskun T, Sloop KW, Samms RJ. Is glucagon receptor activation the thermogenic solution for treating obesity?? Front Endocrinol (Lausanne). 2022;13: 868037.<pub-id pub-id-type="pmid">35547006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2022.868037</pub-id><pub-id pub-id-type="pmcid">PMC9081793</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Day</surname><given-names>JW</given-names></name><name name-style="western"><surname>Gelfanov</surname><given-names>V</given-names></name><name name-style="western"><surname>Smiley</surname><given-names>D</given-names></name><name name-style="western"><surname>Carrington</surname><given-names>PE</given-names></name><name name-style="western"><surname>Eiermann</surname><given-names>G</given-names></name><name name-style="western"><surname>Chicchi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents</article-title><source>Biopolymers</source><year>2012</year><volume>98</volume><fpage>443</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">23203689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bip.22072</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Day JW, Gelfanov V, Smiley D, Carrington PE, Eiermann G, Chicchi G, et al. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Biopolymers. 2012;98:443&#8211;50.<pub-id pub-id-type="pmid">23203689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bip.22072</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clemmensen</surname><given-names>C</given-names></name><name name-style="western"><surname>Chabenne</surname><given-names>J</given-names></name><name name-style="western"><surname>Finan</surname><given-names>B</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>L</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>K</given-names></name><name name-style="western"><surname>K&#252;chler</surname><given-names>D</given-names></name><etal/></person-group><article-title>GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet</article-title><source>Diabetes</source><year>2014</year><volume>63</volume><fpage>1422</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">24379349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db13-1609</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Clemmensen C, Chabenne J, Finan B, Sullivan L, Fischer K, K&#252;chler D, et al. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes. 2014;63:1422&#8211;7.<pub-id pub-id-type="pmid">24379349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db13-1609</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Day</surname><given-names>JW</given-names></name><name name-style="western"><surname>Ottaway</surname><given-names>N</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>JT</given-names></name><name name-style="western"><surname>Gelfanov</surname><given-names>V</given-names></name><name name-style="western"><surname>Smiley</surname><given-names>D</given-names></name><name name-style="western"><surname>Gidda</surname><given-names>J</given-names></name><etal/></person-group><article-title>A new glucagon and GLP-1 co-agonist eliminates obesity in rodents</article-title><source>Nat Chem Biol</source><year>2009</year><volume>5</volume><fpage>749</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">19597507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nchembio.209</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5:749&#8211;57.<pub-id pub-id-type="pmid">19597507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nchembio.209</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>L</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>W</given-names></name><name name-style="western"><surname>Liao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><fpage>8289</fpage><pub-id pub-id-type="pmid">38092790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-44067-4</pub-id><pub-id pub-id-type="pmcid">PMC10719339</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Ji L, Jiang H, Cheng Z, Qiu W, Liao L, Zhang Y, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023;14: 8289.<pub-id pub-id-type="pmid">38092790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-44067-4</pub-id><pub-id pub-id-type="pmcid">PMC10719339</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boland</surname><given-names>ML</given-names></name><name name-style="western"><surname>Laker</surname><given-names>RC</given-names></name><name name-style="western"><surname>Mather</surname><given-names>K</given-names></name><name name-style="western"><surname>Nawrocki</surname><given-names>A</given-names></name><name name-style="western"><surname>Oldham</surname><given-names>S</given-names></name><name name-style="western"><surname>Boland</surname><given-names>BB</given-names></name><etal/></person-group><article-title>Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis</article-title><source>Nat Metab</source><year>2020</year><volume>2</volume><fpage>413</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">32478287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-020-0209-6</pub-id><pub-id pub-id-type="pmcid">PMC7258337</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Boland ML, Laker RC, Mather K, Nawrocki A, Oldham S, Boland BB, et al. Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab. 2020;2:413&#8211;31.<pub-id pub-id-type="pmid">32478287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-020-0209-6</pub-id><pub-id pub-id-type="pmcid">PMC7258337</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finan</surname><given-names>B</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B</given-names></name><name name-style="western"><surname>Ottaway</surname><given-names>N</given-names></name><name name-style="western"><surname>Smiley</surname><given-names>DL</given-names></name><name name-style="western"><surname>Ma</surname><given-names>T</given-names></name><name name-style="western"><surname>Clemmensen</surname><given-names>C</given-names></name><etal/></person-group><article-title>A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents</article-title><source>Nat Med</source><year>2015</year><volume>21</volume><fpage>27</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">25485909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.3761</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21:27&#8211;36.<pub-id pub-id-type="pmid">25485909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.3761</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gutgesell</surname><given-names>RM</given-names></name><name name-style="western"><surname>Nogueiras</surname><given-names>R</given-names></name><name name-style="western"><surname>Tsch&#246;p</surname><given-names>MH</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>TD</given-names></name></person-group><article-title>Dual and triple incretin-based co-agonists: novel therapeutics for obesity and diabetes</article-title><source>Diabetes Ther</source><year>2024</year><volume>15</volume><fpage>1069</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">38573467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13300-024-01566-x</pub-id><pub-id pub-id-type="pmcid">PMC11043266</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Gutgesell RM, Nogueiras R, Tsch&#246;p MH, M&#252;ller TD. Dual and triple incretin-based co-agonists: novel therapeutics for obesity and diabetes. Diabetes Ther. 2024;15:1069&#8211;84.<pub-id pub-id-type="pmid">38573467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13300-024-01566-x</pub-id><pub-id pub-id-type="pmcid">PMC11043266</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jastreboff</surname><given-names>AM</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>LM</given-names></name><name name-style="western"><surname>Fr&#237;as</surname><given-names>JP</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gurbuz</surname><given-names>S</given-names></name><etal/></person-group><article-title>Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial</article-title><source>N Engl J Med</source><year>2023</year><volume>389</volume><fpage>514</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">37366315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2301972</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Jastreboff AM, Kaplan LM, Fr&#237;as JP, Wu Q, Du Y, Gurbuz S, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023;389:514&#8211;26.<pub-id pub-id-type="pmid">37366315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2301972</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Svoboda</surname><given-names>M</given-names></name><name name-style="western"><surname>Tastenoy</surname><given-names>M</given-names></name><name name-style="western"><surname>Vertongen</surname><given-names>P</given-names></name><name name-style="western"><surname>Robberecht</surname><given-names>P</given-names></name></person-group><article-title>Relative quantitative analysis of glucagon receptor mRNA in rat tissues</article-title><source>Mol Cell Endocrinol</source><year>1994</year><volume>105</volume><fpage>131</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7859919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0303-7207(94)90162-7</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Svoboda M, Tastenoy M, Vertongen P, Robberecht P. Relative quantitative analysis of glucagon receptor mRNA in rat tissues. Mol Cell Endocrinol. 1994;105:131&#8211;7.<pub-id pub-id-type="pmid">7859919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0303-7207(94)90162-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beaudry</surname><given-names>JL</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>KD</given-names></name><name name-style="western"><surname>Varin</surname><given-names>EM</given-names></name><name name-style="western"><surname>Baggio</surname><given-names>LL</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X</given-names></name><name name-style="western"><surname>Mulvihill</surname><given-names>EE</given-names></name><etal/></person-group><article-title>The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice</article-title><source>Mol Metab</source><year>2019</year><volume>22</volume><fpage>37</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">30772257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2019.01.011</pub-id><pub-id pub-id-type="pmcid">PMC6437632</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Beaudry JL, Kaur KD, Varin EM, Baggio LL, Cao X, Mulvihill EE, et al. The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice. Mol Metab. 2019;22:37&#8211;48.<pub-id pub-id-type="pmid">30772257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2019.01.011</pub-id><pub-id pub-id-type="pmcid">PMC6437632</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasileva</surname><given-names>A</given-names></name><name name-style="western"><surname>Marx</surname><given-names>T</given-names></name><name name-style="western"><surname>Beaudry</surname><given-names>JL</given-names></name><name name-style="western"><surname>Stern</surname><given-names>JH</given-names></name></person-group><article-title>Glucagon receptor signaling at white adipose tissue does not regulate lipolysis</article-title><source>Am J Physiol Endocrinol Metab</source><year>2022</year><volume>323</volume><fpage>E389</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">36002172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpendo.00078.2022</pub-id><pub-id pub-id-type="pmcid">PMC9576180</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Vasileva A, Marx T, Beaudry JL, Stern JH. Glucagon receptor signaling at white adipose tissue does not regulate lipolysis. Am J Physiol Endocrinol Metab. 2022;323:E389&#8211;401.<pub-id pub-id-type="pmid">36002172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpendo.00078.2022</pub-id><pub-id pub-id-type="pmcid">PMC9576180</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slavin</surname><given-names>BG</given-names></name><name name-style="western"><surname>Ong</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kern</surname><given-names>PA</given-names></name></person-group><article-title>Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes</article-title><source>J Lipid Res</source><year>1994</year><volume>35</volume><fpage>1535</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">7806967</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Slavin BG, Ong JM, Kern PA. Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes. J Lipid Res. 1994;35:1535&#8211;41.<pub-id pub-id-type="pmid">7806967</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prigge</surname><given-names>WF</given-names></name><name name-style="western"><surname>Grande</surname><given-names>F</given-names></name></person-group><article-title>Effects of glucagon, epinephrine and insulin on in vitro lipolysis of adipose tissue from mammals and birds</article-title><source>Comp Biochem Physiol B</source><year>1971</year><volume>39</volume><fpage>69</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">5570026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0305-0491(71)90254-9</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Prigge WF, Grande F. Effects of glucagon, epinephrine and insulin on in vitro lipolysis of adipose tissue from mammals and birds. Comp Biochem Physiol B. 1971;39:69&#8211;82.<pub-id pub-id-type="pmid">5570026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0305-0491(71)90254-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heckemeyer</surname><given-names>CM</given-names></name><name name-style="western"><surname>Barker</surname><given-names>J</given-names></name><name name-style="western"><surname>Duckworth</surname><given-names>WC</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>SS</given-names></name></person-group><article-title>Studies of the biological effect and degradation of glucagon in the rat perifused isolated adipose cell</article-title><source>Endocrinology</source><year>1983</year><volume>113</volume><fpage>270</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">6861701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/endo-113-1-270</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Heckemeyer CM, Barker J, Duckworth WC, Solomon SS. Studies of the biological effect and degradation of glucagon in the rat perifused isolated adipose cell. Endocrinology. 1983;113:270&#8211;6.<pub-id pub-id-type="pmid">6861701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/endo-113-1-270</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arafat</surname><given-names>AM</given-names></name><name name-style="western"><surname>Kaczmarek</surname><given-names>P</given-names></name><name name-style="western"><surname>Skrzypski</surname><given-names>M</given-names></name><name name-style="western"><surname>Pruszy&#324;ska-Oszmalek</surname><given-names>E</given-names></name><name name-style="western"><surname>Ko&#322;odziejski</surname><given-names>P</given-names></name><name name-style="western"><surname>Szczepankiewicz</surname><given-names>D</given-names></name><etal/></person-group><article-title>Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis?</article-title><source>Diabetologia</source><year>2013</year><volume>56</volume><fpage>588</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">23262585</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-012-2803-y</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Arafat AM, Kaczmarek P, Skrzypski M, Pruszy&#324;ska-Oszmalek E, Ko&#322;odziejski P, Szczepankiewicz D, et al. Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis? Diabetologia. 2013;56:588&#8211;97.<pub-id pub-id-type="pmid">23262585</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-012-2803-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gravholt</surname><given-names>CH</given-names></name><name name-style="western"><surname>M&#248;ller</surname><given-names>N</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>MD</given-names></name><name name-style="western"><surname>Christiansen</surname><given-names>JS</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>O</given-names></name></person-group><article-title>Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis</article-title><source>J Clin Endocrinol Metab</source><year>2001</year><volume>86</volume><fpage>2085</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11344211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jcem.86.5.7460</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Gravholt CH, M&#248;ller N, Jensen MD, Christiansen JS, Schmitz O. Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis. J Clin Endocrinol Metab. 2001;86:2085&#8211;9.<pub-id pub-id-type="pmid">11344211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jcem.86.5.7460</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>T</given-names></name><name name-style="western"><surname>Nason</surname><given-names>S</given-names></name><name name-style="western"><surname>Holleman</surname><given-names>C</given-names></name><name name-style="western"><surname>Pepin</surname><given-names>M</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>L</given-names></name><name name-style="western"><surname>Berryhill</surname><given-names>TF</given-names></name><etal/></person-group><article-title>Glucagon receptor signaling regulates energy metabolism via hepatic farnesoid X receptor and fibroblast growth factor 21</article-title><source>Diabetes</source><year>2018</year><volume>67</volume><fpage>1773</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">29925501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db17-1502</pub-id><pub-id pub-id-type="pmcid">PMC6110317</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Kim T, Nason S, Holleman C, Pepin M, Wilson L, Berryhill TF, et al. Glucagon receptor signaling regulates energy metabolism via hepatic farnesoid X receptor and fibroblast growth factor 21. Diabetes. 2018;67:1773&#8211;82.<pub-id pub-id-type="pmid">29925501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db17-1502</pub-id><pub-id pub-id-type="pmcid">PMC6110317</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Habegger</surname><given-names>KM</given-names></name><name name-style="western"><surname>Stemmer</surname><given-names>K</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>TD</given-names></name><name name-style="western"><surname>Heppner</surname><given-names>KM</given-names></name><name name-style="western"><surname>Ottaway</surname><given-names>N</given-names></name><etal/></person-group><article-title>Fibroblast growth factor 21 mediates specific glucagon actions</article-title><source>Diabetes</source><year>2013</year><volume>62</volume><fpage>1453</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">23305646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db12-1116</pub-id><pub-id pub-id-type="pmcid">PMC3636653</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Habegger KM, Stemmer K, Cheng C, M&#252;ller TD, Heppner KM, Ottaway N, et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes. 2013;62:1453&#8211;63.<pub-id pub-id-type="pmid">23305646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db12-1116</pub-id><pub-id pub-id-type="pmcid">PMC3636653</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cannon</surname><given-names>B</given-names></name><name name-style="western"><surname>Nedergaard</surname><given-names>J</given-names></name></person-group><article-title>Brown adipose tissue: function and physiological significance</article-title><source>Physiol Rev</source><year>2004</year><volume>84</volume><fpage>277</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">14715917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00015.2003</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004;84:277&#8211;359.<pub-id pub-id-type="pmid">14715917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00015.2003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kajimura</surname><given-names>S</given-names></name><name name-style="western"><surname>Saito</surname><given-names>M</given-names></name></person-group><article-title>A new era in brown adipose tissue biology: molecular control of brown fat development and energy homeostasis</article-title><source>Annu Rev Physiol</source><year>2014</year><volume>76</volume><fpage>225</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">24188710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-physiol-021113-170252</pub-id><pub-id pub-id-type="pmcid">PMC4090362</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Kajimura S, Saito M. A new era in brown adipose tissue biology: molecular control of brown fat development and energy homeostasis. Annu Rev Physiol. 2014;76:225&#8211;49.<pub-id pub-id-type="pmid">24188710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-physiol-021113-170252</pub-id><pub-id pub-id-type="pmcid">PMC4090362</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lowell</surname><given-names>BB</given-names></name><name name-style="western"><surname>S-Susulic</surname><given-names>V</given-names></name><name name-style="western"><surname>Hamann</surname><given-names>A</given-names></name><name name-style="western"><surname>Lawitts</surname><given-names>JA</given-names></name><name name-style="western"><surname>Himms-Hagen</surname><given-names>J</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>BB</given-names></name><etal/></person-group><article-title>Development of obesity in transgenic mice after genetic ablation of brown adipose tissue</article-title><source>Nature</source><year>1993</year><volume>366</volume><fpage>740</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">8264795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/366740a0</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Lowell BB, S-Susulic V, Hamann A, Lawitts JA, Himms-Hagen J, Boyer BB, et al. Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature. 1993;366:740&#8211;2.<pub-id pub-id-type="pmid">8264795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/366740a0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giralt</surname><given-names>M</given-names></name><name name-style="western"><surname>Villarroya</surname><given-names>F</given-names></name></person-group><article-title>Mitochondrial uncoupling and the regulation of glucose homeostasis</article-title><source>Curr Diabetes Rev</source><year>2017</year><volume>13</volume><fpage>386</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">26900134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1573399812666160217122707</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Giralt M, Villarroya F. Mitochondrial uncoupling and the regulation of glucose homeostasis. Curr Diabetes Rev. 2017;13:386&#8211;94.<pub-id pub-id-type="pmid">26900134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1573399812666160217122707</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartelt</surname><given-names>A</given-names></name><name name-style="western"><surname>Bruns</surname><given-names>OT</given-names></name><name name-style="western"><surname>Reimer</surname><given-names>R</given-names></name><name name-style="western"><surname>Hohenberg</surname><given-names>H</given-names></name><name name-style="western"><surname>Ittrich</surname><given-names>H</given-names></name><name name-style="western"><surname>Peldschus</surname><given-names>K</given-names></name><etal/></person-group><article-title>Brown adipose tissue activity controls triglyceride clearance</article-title><source>Nat Med</source><year>2011</year><volume>17</volume><fpage>200</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">21258337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.2297</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, et al. Brown adipose tissue activity controls triglyceride clearance. Nat Med. 2011;17:200&#8211;5.<pub-id pub-id-type="pmid">21258337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.2297</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villarroya</surname><given-names>F</given-names></name><name name-style="western"><surname>Cereijo</surname><given-names>R</given-names></name><name name-style="western"><surname>Villarroya</surname><given-names>J</given-names></name><name name-style="western"><surname>Giralt</surname><given-names>M</given-names></name></person-group><article-title>Brown adipose tissue as a secretory organ</article-title><source>Nat Rev Endocrinol</source><year>2017</year><volume>13</volume><fpage>26</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">27616452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrendo.2016.136</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Villarroya F, Cereijo R, Villarroya J, Giralt M. Brown adipose tissue as a secretory organ. Nat Rev Endocrinol. 2017;13:26&#8211;35.<pub-id pub-id-type="pmid">27616452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrendo.2016.136</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becher</surname><given-names>T</given-names></name><name name-style="western"><surname>Palanisamy</surname><given-names>S</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Eljalby</surname><given-names>M</given-names></name><name name-style="western"><surname>Marx</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Wibmer</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Brown adipose tissue is associated with cardiometabolic health</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><fpage>58</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">33398160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-1126-7</pub-id><pub-id pub-id-type="pmcid">PMC8461455</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Becher T, Palanisamy S, Kramer DJ, Eljalby M, Marx SJ, Wibmer AG, et al. Brown adipose tissue is associated with cardiometabolic health. Nat Med. 2021;27:58&#8211;65.<pub-id pub-id-type="pmid">33398160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-1126-7</pub-id><pub-id pub-id-type="pmcid">PMC8461455</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giralt</surname><given-names>M</given-names></name><name name-style="western"><surname>Villarroya</surname><given-names>F</given-names></name></person-group><article-title>White, brown, beige/brite: different adipose cells for different functions?</article-title><source>Endocrinology</source><year>2013</year><volume>154</volume><fpage>2992</fpage><lpage>3000</lpage><pub-id pub-id-type="pmid">23782940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2013-1403</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Giralt M, Villarroya F. White, brown, beige/brite: different adipose cells for different functions? Endocrinology. 2013;154:2992&#8211;3000.<pub-id pub-id-type="pmid">23782940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2013-1403</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>P</given-names></name><name name-style="western"><surname>Kajimura</surname><given-names>S</given-names></name></person-group><article-title>The cellular and functional complexity of thermogenic fat</article-title><source>Nat Rev Mol Cell Biol</source><year>2021</year><volume>22</volume><fpage>393</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">33758402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-021-00350-0</pub-id><pub-id pub-id-type="pmcid">PMC8159882</pub-id></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Cohen P, Kajimura S. The cellular and functional complexity of thermogenic fat. Nat Rev Mol Cell Biol. 2021;22:393&#8211;409.<pub-id pub-id-type="pmid">33758402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-021-00350-0</pub-id><pub-id pub-id-type="pmcid">PMC8159882</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vargas-Castillo</surname><given-names>A</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Smythers</surname><given-names>AL</given-names></name><name name-style="western"><surname>Grauvogel</surname><given-names>L</given-names></name><name name-style="western"><surname>Dumesic</surname><given-names>PA</given-names></name><name name-style="western"><surname>Emont</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Development of a functional beige fat cell line uncovers independent subclasses of cells expressing UCP1 and the futile creatine cycle</article-title><source>Cell Metab</source><year>2024</year><volume>36</volume><fpage>2146</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">39084217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2024.07.002</pub-id><pub-id pub-id-type="pmcid">PMC12005060</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Vargas-Castillo A, Sun Y, Smythers AL, Grauvogel L, Dumesic PA, Emont MP, et al. Development of a functional beige fat cell line uncovers independent subclasses of cells expressing UCP1 and the futile creatine cycle. Cell Metab. 2024;36:2146&#8211;55.<pub-id pub-id-type="pmid">39084217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2024.07.002</pub-id><pub-id pub-id-type="pmcid">PMC12005060</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>AK</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Maushart</surname><given-names>CI</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>A</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Single-nucleus transcriptomics identifies separate classes of UCP1 and futile cycle adipocytes</article-title><source>Cell Metab</source><year>2024</year><volume>36</volume><fpage>2130</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">39084216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2024.07.005</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Wang T, Sharma AK, Wu C, Maushart CI, Ghosh A, Yang W, et al. Single-nucleus transcriptomics identifies separate classes of UCP1 and futile cycle adipocytes. Cell Metab. 2024;36:2130&#8211;45.<pub-id pub-id-type="pmid">39084216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2024.07.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yen</surname><given-names>M</given-names></name><name name-style="western"><surname>Ewald</surname><given-names>MB</given-names></name></person-group><article-title>Toxicity of weight loss agents</article-title><source>J Med Toxicol</source><year>2012</year><volume>8</volume><fpage>145</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">22351299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13181-012-0213-7</pub-id><pub-id pub-id-type="pmcid">PMC3550246</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Yen M, Ewald MB. Toxicity of weight loss agents. J Med Toxicol. 2012;8:145&#8211;52.<pub-id pub-id-type="pmid">22351299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13181-012-0213-7</pub-id><pub-id pub-id-type="pmcid">PMC3550246</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobsen</surname><given-names>JM</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>N</given-names></name><name name-style="western"><surname>Torz</surname><given-names>L</given-names></name><name name-style="western"><surname>Gerstenberg</surname><given-names>MK</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>K</given-names></name><name name-style="western"><surname>&#216;stergaard</surname><given-names>S</given-names></name><etal/></person-group><article-title>Housing mice near vs. below thermoneutrality affects drug-induced weight loss but does not improve prediction of efficacy in humans</article-title><source>Cell Rep</source><year>2024</year><volume>43</volume><fpage>114501</fpage><pub-id pub-id-type="pmid">39067024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2024.114501</pub-id><pub-id pub-id-type="pmcid">PMC11380917</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Jacobsen JM, Petersen N, Torz L, Gerstenberg MK, Pedersen K, &#216;stergaard S, et al. Housing mice near vs. below thermoneutrality affects drug-induced weight loss but does not improve prediction of efficacy in humans. Cell Rep. 2024;43:114501.<pub-id pub-id-type="pmid">39067024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2024.114501</pub-id><pub-id pub-id-type="pmcid">PMC11380917</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nogueiras</surname><given-names>R</given-names></name><name name-style="western"><surname>P&#233;rez-Tilve</surname><given-names>D</given-names></name><name name-style="western"><surname>Veyrat-Durebex</surname><given-names>C</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>DA</given-names></name><name name-style="western"><surname>Varela</surname><given-names>L</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>WG</given-names></name><etal/></person-group><article-title>Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity</article-title><source>J Neurosci</source><year>2009</year><volume>29</volume><fpage>5916</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">19420258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.5977-08.2009</pub-id><pub-id pub-id-type="pmcid">PMC6665241</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Nogueiras R, P&#233;rez-Tilve D, Veyrat-Durebex C, Morgan DA, Varela L, Haynes WG, et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci. 2009;29:5916&#8211;25.<pub-id pub-id-type="pmid">19420258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.5977-08.2009</pub-id><pub-id pub-id-type="pmcid">PMC6665241</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lockie</surname><given-names>SH</given-names></name><name name-style="western"><surname>Heppner</surname><given-names>KM</given-names></name><name name-style="western"><surname>Chaudhary</surname><given-names>N</given-names></name><name name-style="western"><surname>Chabenne</surname><given-names>JR</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>DA</given-names></name><name name-style="western"><surname>Veyrat-Durebex</surname><given-names>C</given-names></name><etal/></person-group><article-title>Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling</article-title><source>Diabetes</source><year>2012</year><volume>61</volume><fpage>2753</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">22933116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db11-1556</pub-id><pub-id pub-id-type="pmcid">PMC3478556</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Lockie SH, Heppner KM, Chaudhary N, Chabenne JR, Morgan DA, Veyrat-Durebex C, et al. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes. 2012;61:2753&#8211;62.<pub-id pub-id-type="pmid">22933116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db11-1556</pub-id><pub-id pub-id-type="pmcid">PMC3478556</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beiroa</surname><given-names>D</given-names></name><name name-style="western"><surname>Imbernon</surname><given-names>M</given-names></name><name name-style="western"><surname>Gallego</surname><given-names>R</given-names></name><name name-style="western"><surname>Senra</surname><given-names>A</given-names></name><name name-style="western"><surname>Herranz</surname><given-names>D</given-names></name><name name-style="western"><surname>Villarroya</surname><given-names>F</given-names></name><etal/></person-group><article-title>GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK</article-title><source>Diabetes</source><year>2014</year><volume>63</volume><fpage>3346</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">24917578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db14-0302</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Beiroa D, Imbernon M, Gallego R, Senra A, Herranz D, Villarroya F, et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes. 2014;63:3346&#8211;58.<pub-id pub-id-type="pmid">24917578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db14-0302</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kooijman</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Parlevliet</surname><given-names>ET</given-names></name><name name-style="western"><surname>Boon</surname><given-names>MR</given-names></name><name name-style="western"><surname>Edelschaap</surname><given-names>D</given-names></name><name name-style="western"><surname>Snaterse</surname><given-names>G</given-names></name><etal/></person-group><article-title>Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice</article-title><source>Diabetologia</source><year>2015</year><volume>58</volume><fpage>2637</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">26254578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-015-3727-0</pub-id><pub-id pub-id-type="pmcid">PMC4589565</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Kooijman S, Wang Y, Parlevliet ET, Boon MR, Edelschaap D, Snaterse G, et al. Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice. Diabetologia. 2015;58:2637&#8211;46.<pub-id pub-id-type="pmid">26254578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-015-3727-0</pub-id><pub-id pub-id-type="pmcid">PMC4589565</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliveira</surname><given-names>FCB</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>CM</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>SA</given-names></name><name name-style="western"><surname>Beserra</surname><given-names>BTS</given-names></name><name name-style="western"><surname>Wajner</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Liraglutide activates type 2 deiodinase and enhances &#946;3-Adrenergic-Induced thermogenesis in mouse adipose tissue</article-title><source>Front Endocrinol (Lausanne)</source><year>2021</year><volume>12</volume><fpage>803363</fpage><pub-id pub-id-type="pmid">35069450</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2021.803363</pub-id><pub-id pub-id-type="pmcid">PMC8771968</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Oliveira FCB, Bauer EJ, Ribeiro CM, Pereira SA, Beserra BTS, Wajner SM, et al. Liraglutide activates type 2 deiodinase and enhances &#946;3-Adrenergic-Induced thermogenesis in mouse adipose tissue. Front Endocrinol (Lausanne). 2021;12:803363.<pub-id pub-id-type="pmid">35069450</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2021.803363</pub-id><pub-id pub-id-type="pmcid">PMC8771968</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Can</surname><given-names>J</given-names></name><name name-style="western"><surname>Sloth</surname><given-names>B</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>CB</given-names></name><name name-style="western"><surname>Flint</surname><given-names>A</given-names></name><name name-style="western"><surname>Blaak</surname><given-names>EE</given-names></name><name name-style="western"><surname>Saris</surname><given-names>WHM</given-names></name></person-group><article-title>Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults</article-title><source>Int J Obes (Lond)</source><year>2014</year><volume>38</volume><fpage>784</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">23999198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ijo.2013.162</pub-id><pub-id pub-id-type="pmcid">PMC4052428</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WHM. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014;38:784&#8211;93.<pub-id pub-id-type="pmid">23999198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ijo.2013.162</pub-id><pub-id pub-id-type="pmcid">PMC4052428</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maciel</surname><given-names>MG</given-names></name><name name-style="western"><surname>Beserra</surname><given-names>BTS</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>FCB</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>CM</given-names></name><name name-style="western"><surname>Coelho</surname><given-names>MS</given-names></name><name name-style="western"><surname>Neves F de</surname><given-names>AR</given-names></name><etal/></person-group><article-title>The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure: a systematic review and meta-analysis</article-title><source>Diabetes Res Clin Pract</source><year>2018</year><volume>142</volume><fpage>222</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">29857094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2018.05.034</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Maciel MG, Beserra BTS, Oliveira FCB, Ribeiro CM, Coelho MS, Neves F de AR, et al. The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2018;142:222&#8211;35.<pub-id pub-id-type="pmid">29857094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2018.05.034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Eyk</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Paiman</surname><given-names>EHM</given-names></name><name name-style="western"><surname>Bizino</surname><given-names>MB</given-names></name><name name-style="western"><surname>IJzermans</surname><given-names>SL</given-names></name><name name-style="western"><surname>Kleiburg</surname><given-names>F</given-names></name><name name-style="western"><surname>Boers</surname><given-names>TGW</given-names></name><etal/></person-group><article-title>Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes</article-title><source>Nutr Metab Cardiovasc Dis</source><year>2020</year><volume>30</volume><fpage>616</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">32127340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.numecd.2019.12.005</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">van Eyk HJ, Paiman EHM, Bizino MB, IJzermans SL, Kleiburg F, Boers TGW, et al. Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2020;30:616&#8211;24.<pub-id pub-id-type="pmid">32127340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.numecd.2019.12.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janssen</surname><given-names>LGM</given-names></name><name name-style="western"><surname>Nahon</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Brack&#233;</surname><given-names>KFM</given-names></name><name name-style="western"><surname>van den Broek</surname><given-names>D</given-names></name><name name-style="western"><surname>Smit</surname><given-names>R</given-names></name><name name-style="western"><surname>Sardjoe Mishre</surname><given-names>ASD</given-names></name><etal/></person-group><article-title>Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males</article-title><source>Metabolism</source><year>2020</year><volume>106</volume><fpage>154167</fpage><pub-id pub-id-type="pmid">31982480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.metabol.2020.154167</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Janssen LGM, Nahon KJ, Brack&#233; KFM, van den Broek D, Smit R, Sardjoe Mishre ASD, et al. Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males. Metabolism. 2020;106:154167.<pub-id pub-id-type="pmid">31982480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.metabol.2020.154167</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>KY</given-names></name><name name-style="western"><surname>Cypess</surname><given-names>AM</given-names></name><name name-style="western"><surname>Laughlin</surname><given-names>MR</given-names></name><name name-style="western"><surname>Haft</surname><given-names>CR</given-names></name><name name-style="western"><surname>Hu</surname><given-names>HH</given-names></name><name name-style="western"><surname>Bredella</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Brown adipose reporting criteria in imaging studies (BARCIST 1.0): recommendations for standardized FDG-PET/CT experiments in humans</article-title><source>Cell Metab</source><year>2016</year><volume>24</volume><fpage>210</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">27508870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2016.07.014</pub-id><pub-id pub-id-type="pmcid">PMC4981083</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Chen KY, Cypess AM, Laughlin MR, Haft CR, Hu HH, Bredella MA, et al. Brown adipose reporting criteria in imaging studies (BARCIST 1.0): recommendations for standardized FDG-PET/CT experiments in humans. Cell Metab. 2016;24:210&#8211;22.<pub-id pub-id-type="pmid">27508870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2016.07.014</pub-id><pub-id pub-id-type="pmcid">PMC4981083</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>DB</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>AL</given-names></name><name name-style="western"><surname>Tansey</surname><given-names>JB</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Wood</surname><given-names>CB</given-names></name><name name-style="western"><surname>Nedzi</surname><given-names>L</given-names></name><etal/></person-group><article-title>Brown adipose tissue mimicking head and neck cancer on PET scan in a patient on GLP-1 drug</article-title><source>Laryngoscope</source><year>2025</year><volume>135</volume><fpage>741</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">39370986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/lary.31815</pub-id><pub-id pub-id-type="pmcid">PMC11729570</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Harrison DB, Phillips AL, Tansey JB, Clarke TJ, Wood CB, Nedzi L, et al. Brown adipose tissue mimicking head and neck cancer on PET scan in a patient on GLP-1 drug. Laryngoscope. 2025;135:741&#8211;3.<pub-id pub-id-type="pmid">39370986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/lary.31815</pub-id><pub-id pub-id-type="pmcid">PMC11729570</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lynch</surname><given-names>L</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>AE</given-names></name><name name-style="western"><surname>Duquette</surname><given-names>D</given-names></name><name name-style="western"><surname>Lester</surname><given-names>C</given-names></name><name name-style="western"><surname>Banks</surname><given-names>A</given-names></name><name name-style="western"><surname>LeClair</surname><given-names>K</given-names></name><etal/></person-group><article-title>iNKT cells induce FGF21 for thermogenesis and are required for maximal weight loss in GLP1 therapy</article-title><source>Cell Metab</source><year>2016</year><volume>24</volume><fpage>510</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">27593966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2016.08.003</pub-id><pub-id pub-id-type="pmcid">PMC5061124</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Lynch L, Hogan AE, Duquette D, Lester C, Banks A, LeClair K, et al. iNKT cells induce FGF21 for thermogenesis and are required for maximal weight loss in GLP1 therapy. Cell Metab. 2016;24:510&#8211;9.<pub-id pub-id-type="pmid">27593966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2016.08.003</pub-id><pub-id pub-id-type="pmcid">PMC5061124</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>TDV</given-names></name><name name-style="western"><surname>Fathi</surname><given-names>P</given-names></name><name name-style="western"><surname>Watters</surname><given-names>AB</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Besing</surname><given-names>G-LK</given-names></name><name name-style="western"><surname>Bozadjieva-Kramer</surname><given-names>N</given-names></name><etal/></person-group><article-title>Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets</article-title><source>Mol Metab</source><year>2023</year><volume>72</volume><fpage>101718</fpage><pub-id pub-id-type="pmid">37030441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2023.101718</pub-id><pub-id pub-id-type="pmcid">PMC10131131</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Le TDV, Fathi P, Watters AB, Ellis BJ, Besing G-LK, Bozadjieva-Kramer N, et al. Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets. Mol Metab. 2023;72:101718.<pub-id pub-id-type="pmid">37030441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2023.101718</pub-id><pub-id pub-id-type="pmcid">PMC10131131</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pal</surname><given-names>M</given-names></name><name name-style="western"><surname>Febbraio</surname><given-names>MA</given-names></name><name name-style="western"><surname>Whitham</surname><given-names>M</given-names></name></person-group><article-title>From cytokine to myokine: the emerging role of interleukin-6 in metabolic regulation</article-title><source>Immunol Cell Biol</source><year>2014</year><volume>92</volume><fpage>331</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">24751614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/icb.2014.16</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Pal M, Febbraio MA, Whitham M. From cytokine to myokine: the emerging role of interleukin-6 in metabolic regulation. Immunol Cell Biol. 2014;92:331&#8211;9.<pub-id pub-id-type="pmid">24751614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/icb.2014.16</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bur&#253;sek</surname><given-names>L</given-names></name><name name-style="western"><surname>Houstek</surname><given-names>J</given-names></name></person-group><article-title>Beta-Adrenergic stimulation of interleukin-1alpha and interleukin-6 expression in mouse brown adipocytes</article-title><source>FEBS Lett</source><year>1997</year><volume>411</volume><fpage>83</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9247147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0014-5793(97)00671-6</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Bur&#253;sek L, Houstek J. Beta-Adrenergic stimulation of interleukin-1alpha and interleukin-6 expression in mouse brown adipocytes. FEBS Lett. 1997;411:83&#8211;6.<pub-id pub-id-type="pmid">9247147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0014-5793(97)00671-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heise</surname><given-names>T</given-names></name><name name-style="western"><surname>DeVries</surname><given-names>JH</given-names></name><name name-style="western"><surname>Urva</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Pratt</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes</article-title><source>Diabetes Care</source><year>2023</year><volume>46</volume><fpage>998</fpage><lpage>1004</lpage><pub-id pub-id-type="pmid">36857477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc22-1710</pub-id><pub-id pub-id-type="pmcid">PMC10154650</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care. 2023;46:998&#8211;1004.<pub-id pub-id-type="pmid">36857477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc22-1710</pub-id><pub-id pub-id-type="pmcid">PMC10154650</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beauregard</surname><given-names>N</given-names></name><name name-style="western"><surname>McInnis</surname><given-names>K</given-names></name><name name-style="western"><surname>Goldfield</surname><given-names>GS</given-names></name><name name-style="western"><surname>Doucet</surname><given-names>&#201;</given-names></name></person-group><article-title>Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists</article-title><source>Curr Opin Clin Nutr Metab Care</source><year>2024</year><volume>27</volume><fpage>472</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">39150432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MCO.0000000000001064</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Beauregard N, McInnis K, Goldfield GS, Doucet &#201;. Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists. Curr Opin Clin Nutr Metab Care. 2024;27:472&#8211;8.<pub-id pub-id-type="pmid">39150432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MCO.0000000000001064</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><mixed-citation publication-type="other">Samms RJ, Zhang GF, He W, Ilkayeva O, Droz BA, Bauer SM, et al. Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue. Mol Metab. 2022;64.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2022.101550</pub-id><pub-id pub-id-type="pmcid">PMC9396640</pub-id><pub-id pub-id-type="pmid">35921984</pub-id></mixed-citation></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoneshiro</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Tajima</surname><given-names>K</given-names></name><name name-style="western"><surname>Matsushita</surname><given-names>M</given-names></name><name name-style="western"><surname>Maki</surname><given-names>H</given-names></name><name name-style="western"><surname>Igarashi</surname><given-names>K</given-names></name><etal/></person-group><article-title>BCAA catabolism in brown fat controls energy homeostasis through SLC25A44</article-title><source>Nature</source><year>2019</year><volume>572</volume><fpage>614</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">31435015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-019-1503-x</pub-id><pub-id pub-id-type="pmcid">PMC6715529</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Yoneshiro T, Wang Q, Tajima K, Matsushita M, Maki H, Igarashi K, et al. BCAA catabolism in brown fat controls energy homeostasis through SLC25A44. Nature. 2019;572:614&#8211;9.<pub-id pub-id-type="pmid">31435015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-019-1503-x</pub-id><pub-id pub-id-type="pmcid">PMC6715529</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pirro</surname><given-names>V</given-names></name><name name-style="western"><surname>Roth</surname><given-names>KD</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Willency</surname><given-names>JA</given-names></name><name name-style="western"><surname>Milligan</surname><given-names>PL</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 diabetes</article-title><source>J Clin Endocrinol Metab</source><year>2022</year><volume>107</volume><fpage>363</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">34608929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgab722</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Pirro V, Roth KD, Lin Y, Willency JA, Milligan PL, Wilson JM, et al. Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2022;107:363&#8211;78.<pub-id pub-id-type="pmid">34608929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgab722</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furber</surname><given-names>EC</given-names></name><name name-style="western"><surname>Hyatt</surname><given-names>K</given-names></name><name name-style="western"><surname>Collins</surname><given-names>K</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Droz</surname><given-names>BA</given-names></name><name name-style="western"><surname>Holland</surname><given-names>A</given-names></name><etal/></person-group><article-title>GIPR agonism enhances TZD-induced insulin sensitivity in obese IR mice</article-title><source>Diabetes</source><year>2024</year><volume>73</volume><fpage>292</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">37934926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db23-0172</pub-id><pub-id pub-id-type="pmcid">PMC10796301</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Furber EC, Hyatt K, Collins K, Yu X, Droz BA, Holland A, et al. GIPR agonism enhances TZD-induced insulin sensitivity in obese IR mice. Diabetes. 2024;73:292&#8211;305.<pub-id pub-id-type="pmid">37934926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db23-0172</pub-id><pub-id pub-id-type="pmcid">PMC10796301</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El</surname><given-names>K</given-names></name><name name-style="western"><surname>Douros</surname><given-names>JD</given-names></name><name name-style="western"><surname>Willard</surname><given-names>FS</given-names></name><name name-style="western"><surname>Novikoff</surname><given-names>A</given-names></name><name name-style="western"><surname>Sargsyan</surname><given-names>A</given-names></name><name name-style="western"><surname>Perez-Tilve</surname><given-names>D</given-names></name><etal/></person-group><article-title>The incretin co-agonist Tirzepatide requires GIPR for hormone secretion from human islets</article-title><source>Nat Metab</source><year>2023</year><volume>5</volume><fpage>945</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">37277609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-023-00811-0</pub-id><pub-id pub-id-type="pmcid">PMC10290954</pub-id></element-citation><mixed-citation id="mc-CR139" publication-type="journal">El K, Douros JD, Willard FS, Novikoff A, Sargsyan A, Perez-Tilve D, et al. The incretin co-agonist Tirzepatide requires GIPR for hormone secretion from human islets. Nat Metab. 2023;5:945&#8211;54.<pub-id pub-id-type="pmid">37277609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-023-00811-0</pub-id><pub-id pub-id-type="pmcid">PMC10290954</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergmann</surname><given-names>NC</given-names></name><name name-style="western"><surname>Lund</surname><given-names>A</given-names></name><name name-style="western"><surname>Gasbjerg</surname><given-names>LS</given-names></name><name name-style="western"><surname>Meessen</surname><given-names>ECE</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>MM</given-names></name><name name-style="western"><surname>Bergmann</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study</article-title><source>Diabetologia</source><year>2019</year><volume>62</volume><fpage>665</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">30683945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-018-4810-0</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">Bergmann NC, Lund A, Gasbjerg LS, Meessen ECE, Andersen MM, Bergmann S, et al. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia. 2019;62:665&#8211;75.<pub-id pub-id-type="pmid">30683945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-018-4810-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heimb&#252;rger</surname><given-names>SMN</given-names></name><name name-style="western"><surname>Hoe</surname><given-names>B</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>CN</given-names></name><name name-style="western"><surname>Bergman</surname><given-names>NC</given-names></name><name name-style="western"><surname>Skov-Jeppesen</surname><given-names>K</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>B</given-names></name><etal/></person-group><article-title>GIP affects hepatic fat and brown adipose tissue thermogenesis but not white adipose tissue transcriptome in type 1 diabetes</article-title><source>J Clin Endocrinol Metab</source><year>2022</year><volume>107</volume><fpage>3261</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">36111559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgac542</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Heimb&#252;rger SMN, Hoe B, Nielsen CN, Bergman NC, Skov-Jeppesen K, Hartmann B, et al. GIP affects hepatic fat and brown adipose tissue thermogenesis but not white adipose tissue transcriptome in type 1 diabetes. J Clin Endocrinol Metab. 2022;107:3261&#8211;74.<pub-id pub-id-type="pmid">36111559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgac542</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantelmacher</surname><given-names>FD</given-names></name><name name-style="western"><surname>Zvibel</surname><given-names>I</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>K</given-names></name><name name-style="western"><surname>Epshtein</surname><given-names>A</given-names></name><name name-style="western"><surname>Pasmanik-Chor</surname><given-names>M</given-names></name><name name-style="western"><surname>Vogl</surname><given-names>T</given-names></name><etal/></person-group><article-title>GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9</article-title><source>Nat Metab</source><year>2019</year><volume>1</volume><fpage>58</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">32694806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-018-0001-z</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Mantelmacher FD, Zvibel I, Cohen K, Epshtein A, Pasmanik-Chor M, Vogl T, et al. GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9. Nat Metab. 2019;1:58&#8211;69.<pub-id pub-id-type="pmid">32694806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-018-0001-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Efimova</surname><given-names>I</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>I</given-names></name><name name-style="western"><surname>Zvibel</surname><given-names>I</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>A</given-names></name><name name-style="western"><surname>Mantelmacher</surname><given-names>DF</given-names></name><name name-style="western"><surname>Drucker</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>GIPR signaling in immune cells maintains metabolically beneficial type 2 immune responses in the white fat from obese mice</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>643144</fpage><pub-id pub-id-type="pmid">33717200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.643144</pub-id><pub-id pub-id-type="pmcid">PMC7947693</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Efimova I, Steinberg I, Zvibel I, Neumann A, Mantelmacher DF, Drucker DJ, et al. GIPR signaling in immune cells maintains metabolically beneficial type 2 immune responses in the white fat from obese mice. Front Immunol. 2021;12: 643144.<pub-id pub-id-type="pmid">33717200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.643144</pub-id><pub-id pub-id-type="pmcid">PMC7947693</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villarroya</surname><given-names>F</given-names></name><name name-style="western"><surname>Cereijo</surname><given-names>R</given-names></name><name name-style="western"><surname>Villarroya</surname><given-names>J</given-names></name><name name-style="western"><surname>Gavald&#224;-Navarro</surname><given-names>A</given-names></name><name name-style="western"><surname>Giralt</surname><given-names>M</given-names></name></person-group><article-title>Toward an understanding of how immune cells control brown and beige adipobiology</article-title><source>Cell Metab</source><year>2018</year><volume>27</volume><fpage>954</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">29719233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2018.04.006</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Villarroya F, Cereijo R, Villarroya J, Gavald&#224;-Navarro A, Giralt M. Toward an understanding of how immune cells control brown and beige adipobiology. Cell Metab. 2018;27:954&#8211;61.<pub-id pub-id-type="pmid">29719233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2018.04.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J</given-names></name><etal/></person-group><article-title>Glucose-dependent insulinotropic polypeptide modifies adipose plasticity and promotes beige adipogenesis of human omental adipose-derived stem cells</article-title><source>FASEB J</source><year>2021</year><volume>35</volume><fpage>e21534</fpage><pub-id pub-id-type="pmid">33817830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.201903253R</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Chen X, He X, Guo Y, Liu L, Li H, Tan J, et al. Glucose-dependent insulinotropic polypeptide modifies adipose plasticity and promotes beige adipogenesis of human omental adipose-derived stem cells. FASEB J. 2021;35:e21534.<pub-id pub-id-type="pmid">33817830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.201903253R</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><mixed-citation publication-type="other">Beaudry JL, Drucker DJ. Proglucagon-derived peptides, glucose-dependent insulinotropic polypeptide, and dipeptidyl peptidase-4-mechanisms of action in adipose tissue.&#160;Endocrinol. 2020;161:bqz029.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/endocr/bqz029</pub-id><pub-id pub-id-type="pmid">31782955</pub-id></mixed-citation></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nair</surname><given-names>KS</given-names></name></person-group><article-title>Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency</article-title><source>J Clin Endocrinol Metab</source><year>1987</year><volume>64</volume><fpage>896</fpage><lpage>901</lpage><pub-id pub-id-type="pmid">2881943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jcem-64-5-896</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Nair KS. Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency. J Clin Endocrinol Metab. 1987;64:896&#8211;901.<pub-id pub-id-type="pmid">2881943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jcem-64-5-896</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stahel</surname><given-names>P</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Sud</surname><given-names>SK</given-names></name><name name-style="western"><surname>Floh</surname><given-names>A</given-names></name><name name-style="western"><surname>Dash</surname><given-names>S</given-names></name></person-group><article-title>Intranasal glucagon acutely increases energy expenditure without inducing hyperglycaemia in overweight/obese adults</article-title><source>Diabetes Obes Metab</source><year>2019</year><volume>21</volume><fpage>1357</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">30740846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.13661</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">Stahel P, Lee SJ, Sud SK, Floh A, Dash S. Intranasal glucagon acutely increases energy expenditure without inducing hyperglycaemia in overweight/obese adults. Diabetes Obes Metab. 2019;21:1357&#8211;64.<pub-id pub-id-type="pmid">30740846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.13661</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whytock</surname><given-names>KL</given-names></name><name name-style="western"><surname>Carnero</surname><given-names>EA</given-names></name><name name-style="western"><surname>Vega</surname><given-names>RB</given-names></name><name name-style="western"><surname>Tillner</surname><given-names>J</given-names></name><name name-style="western"><surname>Bock</surname><given-names>C</given-names></name><name name-style="western"><surname>Chivukula</surname><given-names>K</given-names></name><etal/></person-group><article-title>Prolonged glucagon infusion does not affect energy expenditure in individuals with overweight/obesity: a randomized trial</article-title><source>Obesity</source><year>2021</year><volume>29</volume><fpage>1003</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">34029448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/oby.23141</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Whytock KL, Carnero EA, Vega RB, Tillner J, Bock C, Chivukula K, et al. Prolonged glucagon infusion does not affect energy expenditure in individuals with overweight/obesity: a randomized trial. Obesity. 2021;29:1003&#8211;13.<pub-id pub-id-type="pmid">34029448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/oby.23141</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henderson</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Konkar</surname><given-names>A</given-names></name><name name-style="western"><surname>Hornigold</surname><given-names>DC</given-names></name><name name-style="western"><surname>Trevaskis</surname><given-names>JL</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>R</given-names></name><name name-style="western"><surname>Fritsch Fredin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates</article-title><source>Diabetes Obes Metab</source><year>2016</year><volume>18</volume><fpage>1176</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">27377054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.12735</pub-id><pub-id pub-id-type="pmcid">PMC5129521</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Henderson SJ, Konkar A, Hornigold DC, Trevaskis JL, Jackson R, Fritsch Fredin M, et al. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes Metab. 2016;18:1176&#8211;90.<pub-id pub-id-type="pmid">27377054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.12735</pub-id><pub-id pub-id-type="pmcid">PMC5129521</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>TM</given-names></name><name name-style="western"><surname>Field</surname><given-names>BCT</given-names></name><name name-style="western"><surname>McCullough</surname><given-names>KA</given-names></name><name name-style="western"><surname>Troke</surname><given-names>RC</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>ES</given-names></name><name name-style="western"><surname>Salem</surname><given-names>V</given-names></name><etal/></person-group><article-title>Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia</article-title><source>Diabetes</source><year>2013</year><volume>62</volume><fpage>1131</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">23248172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db12-0797</pub-id><pub-id pub-id-type="pmcid">PMC3609580</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">Tan TM, Field BCT, McCullough KA, Troke RC, Chambers ES, Salem V, et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes. 2013;62:1131&#8211;8.<pub-id pub-id-type="pmid">23248172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db12-0797</pub-id><pub-id pub-id-type="pmcid">PMC3609580</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corbin</surname><given-names>KD</given-names></name><name name-style="western"><surname>Carnero</surname><given-names>EA</given-names></name><name name-style="western"><surname>Allerton</surname><given-names>TD</given-names></name><name name-style="western"><surname>Tillner</surname><given-names>J</given-names></name><name name-style="western"><surname>Bock</surname><given-names>CP</given-names></name><name name-style="western"><surname>Luyet</surname><given-names>P-P</given-names></name><etal/></person-group><article-title>Glucagon-like peptide-1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: a randomized trial</article-title><source>Obesity</source><year>2023</year><volume>31</volume><fpage>350</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">36695055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/oby.23633</pub-id><pub-id pub-id-type="pmcid">PMC9881753</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Corbin KD, Carnero EA, Allerton TD, Tillner J, Bock CP, Luyet P-P, et al. Glucagon-like peptide-1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: a randomized trial. Obesity. 2023;31:350&#8211;62.<pub-id pub-id-type="pmid">36695055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/oby.23633</pub-id><pub-id pub-id-type="pmcid">PMC9881753</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Townsend</surname><given-names>LK</given-names></name><name name-style="western"><surname>Medak</surname><given-names>KD</given-names></name><name name-style="western"><surname>Knuth</surname><given-names>CM</given-names></name><name name-style="western"><surname>Peppler</surname><given-names>WT</given-names></name><name name-style="western"><surname>Charron</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Wright</surname><given-names>DC</given-names></name></person-group><article-title>Loss of glucagon signaling alters white adipose tissue browning</article-title><source>FASEB J</source><year>2019</year><volume>33</volume><fpage>4824</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">30615494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.201802048RR</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Townsend LK, Medak KD, Knuth CM, Peppler WT, Charron MJ, Wright DC. Loss of glucagon signaling alters white adipose tissue browning. FASEB J. 2019;33:4824&#8211;35.<pub-id pub-id-type="pmid">30615494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.201802048RR</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spezani</surname><given-names>R</given-names></name><name name-style="western"><surname>Marcondes-de-Castro</surname><given-names>IA</given-names></name><name name-style="western"><surname>Marinho</surname><given-names>TS</given-names></name><name name-style="western"><surname>Reis-Barbosa</surname><given-names>PH</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>LEM</given-names></name><name name-style="western"><surname>Aguila</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Cotadutide improves brown adipose tissue thermogenesis in obese mice</article-title><source>Biochem Pharmacol</source><year>2023</year><volume>217</volume><fpage>115852</fpage><pub-id pub-id-type="pmid">37832793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2023.115852</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Spezani R, Marcondes-de-Castro IA, Marinho TS, Reis-Barbosa PH, Cardoso LEM, Aguila MB, et al. Cotadutide improves brown adipose tissue thermogenesis in obese mice. Biochem Pharmacol. 2023;217:115852.<pub-id pub-id-type="pmid">37832793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2023.115852</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valdecantos</surname><given-names>MP</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>L</given-names></name><name name-style="western"><surname>Folgueira</surname><given-names>C</given-names></name><name name-style="western"><surname>Rada</surname><given-names>P</given-names></name><name name-style="western"><surname>Gomez-Santos</surname><given-names>B</given-names></name><name name-style="western"><surname>Solas</surname><given-names>M</given-names></name><etal/></person-group><article-title>The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><fpage>10342</fpage><pub-id pub-id-type="pmid">39609390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-54080-w</pub-id><pub-id pub-id-type="pmcid">PMC11605122</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Valdecantos MP, Ruiz L, Folgueira C, Rada P, Gomez-Santos B, Solas M, et al. The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk. Nat Commun. 2024;15:10342.<pub-id pub-id-type="pmid">39609390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-54080-w</pub-id><pub-id pub-id-type="pmcid">PMC11605122</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kinoshita</surname><given-names>K</given-names></name><name name-style="western"><surname>Ozaki</surname><given-names>N</given-names></name><name name-style="western"><surname>Takagi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Murata</surname><given-names>Y</given-names></name><name name-style="western"><surname>Oshida</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>Y</given-names></name></person-group><article-title>Glucagon is essential for adaptive thermogenesis in brown adipose tissue</article-title><source>Endocrinology</source><year>2014</year><volume>155</volume><fpage>3484</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">24949663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2014-1175</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Kinoshita K, Ozaki N, Takagi Y, Murata Y, Oshida Y, Hayashi Y. Glucagon is essential for adaptive thermogenesis in brown adipose tissue. Endocrinology. 2014;155:3484&#8211;92.<pub-id pub-id-type="pmid">24949663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2014-1175</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Bostr&#246;m</surname><given-names>P</given-names></name><name name-style="western"><surname>Sparks</surname><given-names>LM</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JH</given-names></name><name name-style="western"><surname>Giang</surname><given-names>A-H</given-names></name><etal/></person-group><article-title>Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human</article-title><source>Cell</source><year>2012</year><volume>150</volume><fpage>366</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">22796012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2012.05.016</pub-id><pub-id pub-id-type="pmcid">PMC3402601</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Wu J, Bostr&#246;m P, Sparks LM, Ye L, Choi JH, Giang A-H, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell. 2012;150:366&#8211;76.<pub-id pub-id-type="pmid">22796012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2012.05.016</pub-id><pub-id pub-id-type="pmcid">PMC3402601</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salem</surname><given-names>V</given-names></name><name name-style="western"><surname>Izzi-Engbeaya</surname><given-names>C</given-names></name><name name-style="western"><surname>Coello</surname><given-names>C</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>DB</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>ES</given-names></name><name name-style="western"><surname>Comninos</surname><given-names>AN</given-names></name><etal/></person-group><article-title>Glucagon increases energy expenditure independently of brown adipose tissue activation in humans</article-title><source>Diabetes Obes Metab</source><year>2016</year><volume>18</volume><fpage>72</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">26434748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.12585</pub-id><pub-id pub-id-type="pmcid">PMC4710848</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Salem V, Izzi-Engbeaya C, Coello C, Thomas DB, Chambers ES, Comninos AN, et al. Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. Diabetes Obes Metab. 2016;18:72&#8211;81.<pub-id pub-id-type="pmid">26434748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.12585</pub-id><pub-id pub-id-type="pmcid">PMC4710848</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hondares</surname><given-names>E</given-names></name><name name-style="western"><surname>Rosell</surname><given-names>M</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Giralt</surname><given-names>M</given-names></name><name name-style="western"><surname>Iglesias</surname><given-names>R</given-names></name><name name-style="western"><surname>Villarroya</surname><given-names>F</given-names></name></person-group><article-title>Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat</article-title><source>Cell Metab</source><year>2010</year><volume>11</volume><fpage>206</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">20197053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2010.02.001</pub-id><pub-id pub-id-type="pmcid">PMC2847690</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Hondares E, Rosell M, Gonzalez FJ, Giralt M, Iglesias R, Villarroya F. Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab. 2010;11:206&#8211;12.<pub-id pub-id-type="pmid">20197053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2010.02.001</pub-id><pub-id pub-id-type="pmcid">PMC2847690</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>FM</given-names></name><name name-style="western"><surname>Kleiner</surname><given-names>S</given-names></name><name name-style="western"><surname>Douris</surname><given-names>N</given-names></name><name name-style="western"><surname>Fox</surname><given-names>EC</given-names></name><name name-style="western"><surname>Mepani</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Verdeguer</surname><given-names>F</given-names></name><etal/></person-group><article-title>FGF21 regulates PGC-1&#945; and browning of white adipose tissues in adaptive thermogenesis</article-title><source>Genes Dev</source><year>2012</year><volume>26</volume><fpage>271</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">22302939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gad.177857.111</pub-id><pub-id pub-id-type="pmcid">PMC3278894</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, et al. FGF21 regulates PGC-1&#945; and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012;26:271&#8211;81.<pub-id pub-id-type="pmid">22302939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gad.177857.111</pub-id><pub-id pub-id-type="pmcid">PMC3278894</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>M</given-names></name><name name-style="western"><surname>Houten</surname><given-names>SM</given-names></name><name name-style="western"><surname>Mataki</surname><given-names>C</given-names></name><name name-style="western"><surname>Christoffolete</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kim</surname><given-names>BW</given-names></name><name name-style="western"><surname>Sato</surname><given-names>H</given-names></name><etal/></person-group><article-title>Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation</article-title><source>Nature</source><year>2006</year><volume>439</volume><fpage>484</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16400329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature04330</pub-id></element-citation><mixed-citation id="mc-CR161" publication-type="journal">Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439:484&#8211;9.<pub-id pub-id-type="pmid">16400329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature04330</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mechanick</surname><given-names>JI</given-names></name><name name-style="western"><surname>Butsch</surname><given-names>WS</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>SM</given-names></name><name name-style="western"><surname>Hamdy</surname><given-names>O</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Prado</surname><given-names>CM</given-names></name><name name-style="western"><surname>Heymsfield</surname><given-names>SB</given-names></name></person-group><article-title>Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity</article-title><source>Obes Rev</source><year>2025</year><volume>26</volume><fpage>e13841</fpage><pub-id pub-id-type="pmid">39295512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/obr.13841</pub-id><pub-id pub-id-type="pmcid">PMC11611443</pub-id></element-citation><mixed-citation id="mc-CR162" publication-type="journal">Mechanick JI, Butsch WS, Christensen SM, Hamdy O, Li Z, Prado CM, Heymsfield SB. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obes Rev. 2025;26:e13841.<pub-id pub-id-type="pmid">39295512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/obr.13841</pub-id><pub-id pub-id-type="pmcid">PMC11611443</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanford</surname><given-names>KI</given-names></name><name name-style="western"><surname>Goodyear</surname><given-names>LJ</given-names></name></person-group><article-title>Muscle-Adipose Tissue Cross Talk</article-title><source>Cold Spring Harb Perspect Med</source><year>2018</year><volume>8</volume><fpage>a029801</fpage><pub-id pub-id-type="pmid">28507197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a029801</pub-id><pub-id pub-id-type="pmcid">PMC5685935</pub-id></element-citation><mixed-citation id="mc-CR163" publication-type="journal">Stanford KI, Goodyear LJ. Muscle-Adipose Tissue Cross Talk. Cold Spring Harb Perspect Med. 2018; 8:a029801<pub-id pub-id-type="pmid">28507197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a029801</pub-id><pub-id pub-id-type="pmcid">PMC5685935</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hata</surname><given-names>M</given-names></name><name name-style="western"><surname>Andriessen</surname><given-names>Emma</given-names></name><name name-style="western"><surname>Hata</surname><given-names>M</given-names></name><name name-style="western"><surname>Diaz-Marin</surname><given-names>R</given-names></name><name name-style="western"><surname>Fournier</surname><given-names>F</given-names></name><name name-style="western"><surname>Crespo-Garcia</surname><given-names>S</given-names></name><etal/></person-group><article-title>Past history of obesity triggers persistent epigenetic changes in innate immunity and exacerbates neuroinflammation</article-title><source>Science</source><year>2023</year><volume>379</volume><fpage>45</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">36603072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abj8894</pub-id></element-citation><mixed-citation id="mc-CR164" publication-type="journal">Hata M, Andriessen EMMA, Hata M, Diaz-Marin R, Fournier F, Crespo-Garcia S, et al. Past history of obesity triggers persistent epigenetic changes in innate immunity and exacerbates neuroinflammation. Science. 2023;379:45&#8211;62. <pub-id pub-id-type="pmid">36603072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abj8894</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Franquesa</surname><given-names>A</given-names></name><name name-style="western"><surname>Gama-Perez</surname><given-names>P</given-names></name><name name-style="western"><surname>Kulis</surname><given-names>M</given-names></name><name name-style="western"><surname>Szczepanowska</surname><given-names>K</given-names></name><name name-style="western"><surname>Dahdah</surname><given-names>N</given-names></name><name name-style="western"><surname>Moreno-Gomez</surname><given-names>S</given-names></name><etal/></person-group><article-title>Remission of obesity and insulin resistance is not sufficient to restore mitochondrial homeostasis in visceral adipose tissue</article-title><source>Redox Biol</source><year>2022</year><volume>54</volume><fpage>102353</fpage><pub-id pub-id-type="pmid">35777200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2022.102353</pub-id><pub-id pub-id-type="pmcid">PMC9287736</pub-id></element-citation><mixed-citation id="mc-CR165" publication-type="journal">Gonzalez-Franquesa A, Gama-Perez P, Kulis M, Szczepanowska K, Dahdah N, Moreno-Gomez S, et al. Remission of obesity and insulin resistance is not sufficient to restore mitochondrial homeostasis in visceral adipose tissue. Redox Biol. 2022;54:102353.<pub-id pub-id-type="pmid">35777200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2022.102353</pub-id><pub-id pub-id-type="pmcid">PMC9287736</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hinte</surname><given-names>LC</given-names></name><name name-style="western"><surname>Castellano-Castillo</surname><given-names>D</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>A</given-names></name><name name-style="western"><surname>Melrose</surname><given-names>K</given-names></name><name name-style="western"><surname>Gasser</surname><given-names>F</given-names></name><name name-style="western"><surname>No&#233;</surname><given-names>F</given-names></name><etal/></person-group><article-title>Adipose tissue retains an epigenetic memory of obesity after weight loss</article-title><source>Nature</source><year>2024</year><volume>636</volume><fpage>457</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">39558077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-024-08165-7</pub-id><pub-id pub-id-type="pmcid">PMC11634781</pub-id></element-citation><mixed-citation id="mc-CR166" publication-type="journal">Hinte LC, Castellano-Castillo D, Ghosh A, Melrose K, Gasser E, No&#233; F, et al. Adipose tissue retains an epigenetic memory of obesity after weight loss. Nature. 2024;636:457&#8211;65.<pub-id pub-id-type="pmid">39558077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-024-08165-7</pub-id><pub-id pub-id-type="pmcid">PMC11634781</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>